<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Pre‐admission antibiotics for suspected cases of meningococcal disease - Sudarsanam, TD - 2017 | Cochrane Library</title> <meta content="Pre‐admission antibiotics for suspected cases of meningococcal disease - Sudarsanam, TD - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005437.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Pre‐admission antibiotics for suspected cases of meningococcal disease - Sudarsanam, TD - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005437.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD005437.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Pre‐admission antibiotics for suspected cases of meningococcal disease" name="citation_title"/> <meta content="Thambu D Sudarsanam" name="citation_author"/> <meta content="Christian Medical College" name="citation_author_institution"/> <meta content="thambu@cmcvellore.ac.in" name="citation_author_email"/> <meta content="Priscilla Rupali" name="citation_author"/> <meta content="Christian Medical College" name="citation_author_institution"/> <meta content="Prathap Tharyan" name="citation_author"/> <meta content="Christian Medical College" name="citation_author_institution"/> <meta content="Ooriapadickal Cherian Abraham" name="citation_author"/> <meta content="Christian Medical College" name="citation_author_institution"/> <meta content="Kurien Thomas" name="citation_author"/> <meta content="Oman Medical Specialty Board" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD005437.pub4" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/06/14" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005437.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005437.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005437.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Antibiotic Prophylaxis; Anti‐Bacterial Agents [therapeutic use]; Ceftriaxone [therapeutic use]; Chloramphenicol [therapeutic use]; Injections, Intramuscular; Meningitis, Meningococcal [complications, drug therapy, mortality]; Meningococcal Infections [complications, *drug therapy, mortality]; Patient Admission" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005437.pub4&amp;doi=10.1002/14651858.CD005437.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005437.pub4&amp;doi=10.1002/14651858.CD005437.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005437.pub4&amp;doi=10.1002/14651858.CD005437.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005437.pub4&amp;doi=10.1002/14651858.CD005437.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005437.pub4&amp;doi=10.1002/14651858.CD005437.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005437.pub4&amp;doi=10.1002/14651858.CD005437.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005437.pub4&amp;doi=10.1002/14651858.CD005437.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005437.pub4&amp;doi=10.1002/14651858.CD005437.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005437.pub4&amp;doi=10.1002/14651858.CD005437.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005437.pub4&amp;doi=10.1002/14651858.CD005437.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005437.pub4&amp;doi=10.1002/14651858.CD005437.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005437.pub4&amp;doi=10.1002/14651858.CD005437.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005437.pub4&amp;doi=10.1002/14651858.CD005437.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005437.pub4&amp;doi=10.1002/14651858.CD005437.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005437.pub4&amp;doi=10.1002/14651858.CD005437.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005437.pub4&amp;doi=10.1002/14651858.CD005437.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005437.pub4&amp;doi=10.1002/14651858.CD005437.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005437.pub4&amp;doi=10.1002/14651858.CD005437.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005437.pub4&amp;doi=10.1002/14651858.CD005437.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005437.pub4&amp;doi=10.1002/14651858.CD005437.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005437.pub4&amp;doi=10.1002/14651858.CD005437.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005437.pub4&amp;doi=10.1002/14651858.CD005437.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005437.pub4&amp;doi=10.1002/14651858.CD005437.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="jiwTpTuf";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD005437\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD005437\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005437\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005437\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ms","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD005437.pub4",title:"Pre\\u2010admission antibiotics for suspected cases of meningococcal disease",firstPublishedDate:"Jun 14, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Acute Respiratory Infections Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jiwTpTuf&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005437.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005437.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD005437.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD005437.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005437.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD005437.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005437.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD005437.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005437.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD005437.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD005437.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD005437.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD005437.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD005437.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3585 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD005437.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005437.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005437.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005437.pub4/full#CD005437-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005437.pub4/full#CD005437-sec-0090"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005437.pub4/full#CD005437-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005437.pub4/full#CD005437-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005437.pub4/full#CD005437-sec-0031"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005437.pub4/full#CD005437-sec-0032"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005437.pub4/full#CD005437-sec-0056"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005437.pub4/full#CD005437-sec-0076"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD005437.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005437.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005437.pub4/appendices#CD005437-sec-0095"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005437.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005437.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD005437.pub4/media/CDSR/CD005437/table_n/CD005437StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD005437.pub4/media/CDSR/CD005437/table_n/CD005437StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005437.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005437.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005437.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005437.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005437.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD005437.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD005437.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Pre‐admission antibiotics for suspected cases of meningococcal disease</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005437.pub4/information#CD005437-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Thambu D Sudarsanam</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005437.pub4/information#CD005437-cr-0003">Priscilla Rupali</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005437.pub4/information#CD005437-cr-0004">Prathap Tharyan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005437.pub4/information#CD005437-cr-0005">Ooriapadickal Cherian Abraham</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005437.pub4/information#CD005437-cr-0006">Kurien Thomas</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD005437.pub4/information/en#CD005437-sec-0105">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 14 June 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD005437.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD005437.pub4">https://doi.org/10.1002/14651858.CD005437.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD005437-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005437-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005437-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005437-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD005437-abs-0008">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD005437-abs-0001" lang="en"> <section id="CD005437-sec-0001"> <h3 class="title" id="CD005437-sec-0001">Background</h3> <p>Meningococcal disease can lead to death or disability within hours after onset. Pre‐admission antibiotics aim to reduce the risk of serious disease and death by preventing delays in starting therapy before confirmation of the diagnosis. </p> </section> <section id="CD005437-sec-0002"> <h3 class="title" id="CD005437-sec-0002">Objectives</h3> <p>To study the effectiveness and safety of pre‐admission antibiotics versus no pre‐admission antibiotics or placebo, and different pre‐admission antibiotic regimens in decreasing mortality, clinical failure, and morbidity in people suspected of meningococcal disease. </p> </section> <section id="CD005437-sec-0003"> <h3 class="title" id="CD005437-sec-0003">Search methods</h3> <p>We searched CENTRAL (6 January 2017), MEDLINE (1966 to 6 January 2017), Embase (1980 to 6 January 2017), Web of Science (1985 to 6 January 2017), LILACS (1982 to 6 January 2017), and prospective trial registries to January 2017. We previously searched CAB Abstracts from 1985 to June 2015, but did not update this search in January 2017. </p> </section> <section id="CD005437-sec-0004"> <h3 class="title" id="CD005437-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) or quasi‐RCTs comparing antibiotics versus placebo or no intervention, in people with suspected meningococcal infection, or different antibiotics administered before admission to hospital or confirmation of the diagnosis. </p> </section> <section id="CD005437-sec-0005"> <h3 class="title" id="CD005437-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed trial quality and extracted data from the search results. We calculated the risk ratio (RR) and 95% confidence interval (CI) for dichotomous data. We included only one trial and so did not perform data synthesis. We assessed the overall quality of the evidence using the GRADE approach. </p> </section> <section id="CD005437-sec-0006"> <h3 class="title" id="CD005437-sec-0006">Main results</h3> <p>We found no RCTs comparing pre‐admission antibiotics versus no pre‐admission antibiotics or placebo. We included one open‐label, non‐inferiority RCT with 510 participants, conducted during an epidemic in Niger, evaluating a single dose of intramuscular ceftriaxone versus a single dose of intramuscular long‐acting (oily) chloramphenicol. Ceftriaxone was not inferior to chloramphenicol in reducing mortality (RR 1.21, 95% CI 0.57 to 2.56; N = 503; 308 confirmed meningococcal meningitis; 26 deaths; moderate‐quality evidence), clinical failures (RR 0.83, 95% CI 0.32 to 2.15; N = 477; 18 clinical failures; moderate‐quality evidence), or neurological sequelae (RR 1.29, 95% CI 0.63 to 2.62; N = 477; 29 with sequelae; low‐quality evidence). No adverse effects of treatment were reported. Estimated treatment costs were similar. No data were available on disease burden due to sequelae. </p> </section> <section id="CD005437-sec-0007"> <h3 class="title" id="CD005437-sec-0007">Authors' conclusions</h3> <p>We found no reliable evidence to support the use pre‐admission antibiotics for suspected cases of non‐severe meningococcal disease. Moderate‐quality evidence from one RCT indicated that single intramuscular injections of ceftriaxone and long‐acting chloramphenicol were equally effective, safe, and economical in reducing serious outcomes. The choice between these antibiotics should be based on affordability, availability, and patterns of antibiotic resistance. </p> <p>Further RCTs comparing different pre‐admission antibiotics, accompanied by intensive supportive measures, are ethically justified in people with less severe illness, and are needed to provide reliable evidence in different clinical settings. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD005437-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005437-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005437-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005437-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD005437-abs-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD005437-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD005437-abs-0002" lang="en"> <h3>Antibiotics to treat suspected cases meningitis due to infection with meningococcus before confirmation of diagnosis </h3> <p><b>Review question</b> </p> <p>We wanted to know if people suspected to have inflammation of the membranes covering the brain and spinal cord (meningitis) due to infection with the meningococcal bacteria should be given antibiotics before the diagnosis is confirmed in order to prevent death or disability. We found one relevant study. </p> <p><b>Background</b> </p> <p>Meningococcal disease is a rapidly progressing, contagious bacterial infection that can cause epidemics of severe disease of the brain and blood. If not treated early many will die or have permanent disabilities. Antibiotics are very effective if given early. Waiting for confirmation of the diagnosis with laboratory tests can result in delays in starting antibiotics. Giving antibiotics early based on a clinical suspicion (empiric treatment) could prevent delays in treatment and consequent death and disability. However, doing so could also result in unnecessary treatment. </p> <p><b>Study characteristics</b> </p> <p>We searched for studies comparing giving versus not giving empiric antibiotics or comparing different antibiotics in those with suspected meningococcal disease. We found one randomised trial comparing single intramuscular doses of two different long‐acting antibiotics. The evidence is current to January 2017. </p> <p>The included study was conducted in nine primary care facilities in Niger during an outbreak of meningococcal disease in 2003. Of 510 adults and children studied, 251 received ceftriaxone and 259 received chloramphenicol. The study was funded by Médecins Sans Frontières. </p> <p><b>Key results</b> </p> <p>There was no difference in the number of people who died, did not respond to treatment, or with neurological disabilities with either antibiotic empirically. The results were similar in whom the diagnosis was subsequently confirmed. Neither antibiotic had significant adverse effects. </p> <p><b>Quality of the evidence</b> </p> <p>Although the study was well conducted, the overall quality of the evidence was only moderate for death and treatment failures because the study excluded children less than two months old, pregnant women, and the severely ill. The quality of evidence was lower for neurological disabilities because of the shortness of follow‐up. </p> <p>Since meningococcal disease has serious consequences, not giving antibiotics empirically would be unethical. However, future research comparing different antibiotics in people of all ages and illness severity is required to provide reliable evidence in different clinical settings. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD005437-sec-0090" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD005437-sec-0090"></div> <h3 class="title" id="CD005437-sec-0091">Implications for practice</h3> <section id="CD005437-sec-0091"> <p>This review update again found no trials to provide reliable evidence to support or refute the routine use of pre‐admission antibiotics for suspected cases of meningococcal disease. </p> <p>The decision to start antibiotics before admission or confirmation of the diagnosis will therefore depend on local health policy. Considering the potential for serious outcomes and rapid evolution of the disease, the routine use of antibiotics when meningococcus meningitis is suspected appears to be supported by the balance of evidence from available observational studies, which suggest that early intervention, coupled with intensive support measures, are beneficial in reducing mortality and morbidity in people suspected to have meningococcal meningitis, and particularly meningococcal septicaemia. </p> <p>When symptoms are milder, false‐positive diagnoses are more likely and close monitoring and investigations to confirm suspicions, and investigations to rule out other infections, are especially warranted. </p> <p>If antibiotics are given before confirmation of the diagnosis, the benefits may outweigh the risks inherent in their use, though this needs to be reviewed on an individual basis. Limited data from the one randomised controlled trial reviewed here, which excluded infants, pregnant women, and those with severe illness, suggest that pre‐admission antibiotics in people suspected to have meningococcal meningitis are more likely to prevent unfavourable outcomes if initiated before the onset of frequent seizures or impaired consciousness, or in the absence of concurrent infections. Early antibiotic treatment should be accompanied by better healthcare delivery that facilitates more rapid and accurate diagnosis, rapid transfer to hospital, and the immediate initiation of intensive supportive measures. </p> <p>While penicillin is commonly recommended as a pre‐admission antibiotic, we found no trials of penicillin for this indication. In the sole trial of pre‐admission antibiotics for meningococcal meningitis identified in this review, single intramuscular injections of ceftriaxone and long‐acting chloramphenicol (with an additional dose in 24 to 48 hours, if clinical recovery was poor) were equally effective and safe in reducing mortality and morbidity in suspected and confirmed cases. Ceftriaxone may also be the cheaper alternative to penicillin (<a href="./references#CD005437-bbs2-0065" title="National Collaborating Centre for Women’s and Children’s Health. Bacterial meningitis and meningococcal septicaemia: the management of bacterial meningitis and meningococcal septicaemia in children and young people younger than 16 years in primary and secondary care. NICE Clinical Guideline CG 102. www.nice.org.uk/CG102 (accessed prior to 2 June 2017). ">NICE 2010</a>). </p> </section> <h3 class="title" id="CD005437-sec-0092">Implications for research</h3> <section id="CD005437-sec-0092"> <p>Meningococcal disease has serious consequences and progresses rapidly in a sizeable proportion of patients. Standard policy in many countries (<a href="./references#CD005437-bbs2-0055" title="HahnéSJM , CharlettA , PurcellB , SamuelssonS , CamaroniI , EhrhardI , et al. Effectiveness of antibiotics given before admission in reducing mortality from meningococcal disease: systematic review. BMJ2006;332:1299‐303. ">Hahné 2006</a>), backed by recommendations from professional associations (<a href="./references#CD005437-bbs2-0065" title="National Collaborating Centre for Women’s and Children’s Health. Bacterial meningitis and meningococcal septicaemia: the management of bacterial meningitis and meningococcal septicaemia in children and young people younger than 16 years in primary and secondary care. NICE Clinical Guideline CG 102. www.nice.org.uk/CG102 (accessed prior to 2 June 2017). ">NICE 2010</a>; <a href="./references#CD005437-bbs2-0078" title="Scottish Intercollegiate Guidelines Network. Management of invasive meningococcal disease in children and young people. A National Clinical Guideline: 102. www.sign.ac.uk/pdf/sign102.pdf (accessed prior to 2 June 2017). ">SIGN 2008</a>), mandates the early initiation of antibiotics, particularly penicillin or a third‐generation cephalosporin, once criteria for bacterial meningitis are met. </p> <p>Under these circumstances, it is unlikely that randomised, placebo‐controlled trials will be conducted to answer the primary question on the efficacy and safety of initiating early antibiotic treatment versus delaying antibiotics until confirmation of the diagnosis in suspected cases of meningococcal meningitis, to prevent deaths and neurological or other disabling or disfiguring sequelae. </p> <p>More accurate and early diagnosis would aid the early and appropriate use of antibiotics. Dot enzyme‐linked immunosorbent assay (Dot‐ELISA) using outer membrane complexes from <i>Neisseria meningitidis B</i> as a target was found to be specific for serologic verification of clinically suspected meningococcal disease in patients; determination of antibody titres produced during different phases of natural infection was also possible (<a href="./references#CD005437-bbs2-0036" title="BeloEFT , FarhatCK , GaspariEND . Comparison of dot‐ELISA and standard ELISA for detection of Neisseria meningitidis outer membrane complex‐specific antibodies. Brazilian Journal of Infectious Diseases2010;14(1):35‐40. ">Belo 2010</a>). The increased use of dip‐stick rapid diagnostic tests (RDTs), which can be easily and accurately used by non‐specialist healthcare personnel in basic healthcare facilities and which are comparable in diagnostic accuracy to polymerase chain reaction diagnosis, will obviate the need to wait until samples are confirmed in reference laboratories, and will aid the decision to institute life‐saving measures early for those diagnosed with meningococcal meningitis (<a href="./references#CD005437-bbs2-0044" title="ChanteauS , RoseAM , DjiboS , NatoF , BoisierP . Biological diagnosis of meningococcal meningitis in the African meningitis belt: current epidemic strategy and new perspectives. Vaccine2007;25(Suppl 1):A30‐6. ">Chanteau 2007</a>). The use of RDTs would also facilitate attempts to use scarce stocks of emergency vaccines more appropriately (<a href="./references#CD005437-bbs2-0037" title="BoisierP , MahamaneAE , HamidouAA , SidikouF , DjiboS , NatoF , et al. Field evaluation of rapid diagnostic tests for meningococcal meningitis in Niger. Tropical Medicine and International Health2009;14:111‐7. ">Boisier 2009</a>). However, the sensitivity of RDTs would need to improve and large‐scale production be stabilised to ensure less batch‐to‐batch variation than is currently observed (<a href="./references#CD005437-bbs2-0072" title="RoseAMC , MuellerJE , GerstlS , Njanpop‐LafourcadeB‐M , PageA‐L , NicolasP , et al. Meningitis dipstick rapid test: evaluating diagnostic performance during an urban Neisseria meningitidis serogroup A outbreak, Burkina Faso, 2007. PLoS ONE2010;5(6):e11086. [DOI: 10.1371/journal.pone.0011086] ">Rose 2010</a>). Molecular testing of nasopharyngeal specimens using loop‐mediated isothermal amplification (LAMP) to detect the <i>ctrA</i> gene involved in <i>N meningitidis</i> capsular transport is a non‐invasive near‐patient diagnostic test that is being evaluated (<a href="./references#CD005437-bbs2-0040" title="BourkeTW , FairleyDJ , ShiledsMD . Rapid diagnosis of meningococcal disease (editorial). Expert Review of Anti‐infective Therapy2010;8(12):1321‐3. ">Bourke 2010</a>). </p> <p>The need for placebo‐controlled trials to guide decisions pertaining to the pre‐hospital use of antibiotics will then have less urgency, due to the shorter times to confirmation of diagnoses. </p> <p>However, randomised controlled trials comparing the efficacy and safety of different pre‐admission antibiotics, particularly in comparison with penicillin, are ethically justifiable and are needed to widen the evidence‐base for antibiotics available to clinicians in settings of differing resistance patterns, drug costs, availability, and preferences. </p> <p>Given that the majority of treatment failures and fatalities in many observational studies (<a href="./references#CD005437-bbs2-0046" title="EdmondK ,  ClarkA ,  KorczakVS ,  SandersonC ,  GriffithsUK ,  RudanI . Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta‐analysis. Lancet Infectious Diseases2010;10(5):317‐28. ">Edmond 2010</a>; <a href="./references#CD005437-bbs2-0022" title="Perea‐MillaE , OlallaJ , Sanchez‐CantalejoE , MartosF , Matute‐CruzP , Carmona‐LopezG , et al. Pre‐hospital antibiotic treatment and mortality caused by invasive meningococcal disease, adjusting for indication bias. BMC Public Health2009;9:95. [Research Support, Non‐U.S. Gov't 19344518] ">Perea‐Milla 2009</a>), and in the sole randomised controlled trial included in this review (<a href="./references#CD005437-bbs2-0001" title="NathanN , BorelT , DjiboA , EvansD , DjiboS , CortyJF , et al. Ceftriaxone as effective as long‐acting chloramphenicol in short‐course treatment of meningococcal meningitis during epidemics: a randomised non‐inferiority study. Lancet2005;366:308‐13. ">Nathan 2005</a>), occurred in those with more severe manifestations of the disease at presentation, the efficacy of immediate antibiotic use needs to be evaluated alongside other immediate measures to prevent death or clinical deterioration. <a href="./references#CD005437-bbs2-0001" title="NathanN , BorelT , DjiboA , EvansD , DjiboS , CortyJF , et al. Ceftriaxone as effective as long‐acting chloramphenicol in short‐course treatment of meningococcal meningitis during epidemics: a randomised non‐inferiority study. Lancet2005;366:308‐13. ">Nathan 2005</a> excluded people with established evidence of serious illness pre‐randomisation, severely ill people, and those in coma or shock. Including people with such characteristics in future trials may be ethically justified if coupled with measures for rapid confirmation of the diagnosis, and if other intensive supportive measures were also given to all participants, or were the focus of specific enquiry, when given along with pre‐admission antibiotics. </p> <p>Trials in those with less severe forms of illness are also both needed and ethically justified. An important issue is the potential for antibiotic resistance should antibiotics be indiscriminately used for this indication. Evidence for the efficacy of pre‐confirmation antibiotic use is particularly important in those with suspected meningitis without indicators of severe disease, as many such cases could eventually be found not to be due to meningitis or due to other aetiologies. Such trials should be adequately powered to detect differences in outcomes between those with and without confirmed meningococcal meningitis, and could stratify participants by levels of severity. </p> <p>However, uncertainties in the speed of, and variations in, disease evolution, and the problems of identifying an ideal threshold of clinical symptoms and signs for inclusion in such trials, given the problems with sensitivity and specificity of clinical diagnostic criteria (unless replaced or supplemented by molecular or dip‐stick rapid diagnostic tests), would pose ethical and logistical problems in the implementation and interpretation of such trials. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD005437-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD005437-sec-0022"></div> <div class="table" id="CD005437-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Ceftriaxone versus long‐acting (oily) chloramphenicol in people suspected to have meningococcal disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Ceftriaxone versus long‐acting (oily) chloramphenicol in people suspected to have meningococcal disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people suspected to have meningococcal disease (adults and children)<br/> <b>Settings:</b> primary care centres in a low‐income country in Africa during an epidemic<br/> <b>Intervention:</b> intramuscular ceftriaxone (100 mg/kg; max 4 g) single dose<br/> <b>Comparison:</b> long‐acting (oily) chloramphenicol (100 mg/kg; max 3 g) single dose </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Long‐acting (oily) chloramphenicol</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Intramuscular ceftriaxone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death ‐ in all participants ‐ short term</b> <br/> Follow‐up: 72 hours </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>47 per 1000</b><sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>57 per 1000</b> <br/> (27 to 120) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.21</b> <br/> (0.57 to 2.56)<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>503<br/> (1 study)<sup>8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3,4,5,6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All outcomes in this table are from 1 trial that randomised 510 participants to either intervention (<a href="./references#CD005437-bbs2-0001" title="NathanN , BorelT , DjiboA , EvansD , DjiboS , CortyJF , et al. Ceftriaxone as effective as long‐acting chloramphenicol in short‐course treatment of meningococcal meningitis during epidemics: a randomised non‐inferiority study. Lancet2005;366:308‐13. ">Nathan 2005</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death ‐ in confirmed cases of meningococcal meningitis (subgroup)</b> <br/> Follow‐up: 72 hours </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 1000</b><sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>38 per 1000</b> <br/> (12 to 121) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.11</b> <br/> (0.35 to 3.56)<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>308<br/> (1 study)<sup>8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3,4,6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical failure ‐ in all participants ‐ short term</b> <br/> Composite clinical criteria<sup>10</sup> <br/> Follow‐up: 24 to 48 hours </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>41 per 1000</b><sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 1000</b> <br/> (13 to 84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.83</b> <br/> (0.32 to 2.15)<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>477<br/> (1 study)<sup>8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3,4,6,7,9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical failure ‐ in confirmed cases of meningococcal meningitis (subgroup)</b> <br/> Composite clinical criteria<sup>10</sup> <br/> Follow‐up: 24 to 48 hours </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>14 per 1000</b><sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>19 per 1000</b> <br/> (3 to 107) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.39</b> <br/> (0.23 to 8.47)<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>308<br/> (1 study)<sup>8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3,4,6,7,9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neurological sequelae ‐ in all participants‐ short term</b> <br/> Clinical assessment<sup>11</sup> <br/> Follow‐up: 72 hours </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>53 per 1000</b><sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>68 per 1000</b> <br/> (33 to 139) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.29</b> <br/> (0.63 to 2.62)<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>477<br/> (1 study)<sup>8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,4,7,9,12,13</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neurological sequelae ‐ in confirmed cases of meningococcal meningitis (subgroup)</b> <br/> Clinical assesment<sup>11</sup> <br/> Follow‐up: 72 hours </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>63 per 1000</b><sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>91 per 1000</b> <br/> (41 to 203) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.44</b> <br/> (0.65 to 3.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>297<br/> (1 study)<sup>8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,4,5,7,9,12</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events ‐ short term</b> <br/> Follow‐up: 72 hours </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (1 study)<sup>8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No adverse events were detected with either intervention</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Basis of the assumed risk: control group risk.<br/> <sup>2</sup>Effect estimate: consistent with non‐inferiority of ceftriaxone versus chloramphenicol.<br/> <sup>3</sup>No serious study limitations: block randomised using off‐site computer‐generated codes in blocks of 20; allocation concealed in numbered, sealed, opaque envelopes; recruitment was by personnel not involved in generating random sequence; baseline variables matched in intervention arms; open‐label trial but outcome was objective; outcomes completely and adequately reported; no other biases.<br/> <sup>4</sup>No serious inconsistency: results for all participants and in subgroups were consistent.<br/> <sup>5</sup>Serious imprecision: sample size was estimated to demonstrate non‐inferiority for the primary outcome and not for neurological sequelae (secondary outcome). A sample size of 175 individuals with confirmed meningococcal meningitis per group (350 total) was needed for the primary outcome with a one‐sided 5% significance level, 80% power, and assuming 10% dropouts. Only 308 participants were confirmed to have meningococcal meningitis, thus trial may be underpowered to detect non‐inferiority for neurological outcomes. Downgraded by one.<br/> <sup>6</sup>No serious imprecision: trial was adequately powered to demonstrate non‐inferiority. Not downgraded.<br/> <sup>7</sup>Publication bias unlikely: search for trials was comprehensive. Not downgraded.<br/> <sup>8</sup>Parallel‐group, open‐label, non‐inferiority trial.<br/> <sup>9</sup>Serious indirectness: trial excluded infants, pregnant women, and those with serious illness (in non‐reactive coma or with convulsions). Downgraded by one.<br/> <sup>10</sup>Clinical failure: composite of: a) state of consciousness remaining severely altered (Glasgow Coma Scale &lt; 11 at 24 hours or &lt; 13 at 48 hours); b) no improvement in the state of consciousness since 0 hour; c) appearance of or worsened neurological symptoms since 0 hour; d) repeated or persistent convulsions; and e) axillary temperature above 38.5° C in the absence of other evident infectious pathological changes.<br/> <sup>11</sup>Neurological sequelae: judged on gross clinical abnormality.<br/> <sup>12</sup>Serious indirectness: follow‐up was too short to detect neurological sequelae adequately. Downgraded by one.<br/> <sup>13</sup>No serious imprecision: sample size of 350 required to demonstrate non‐inferiority for primary outcome, but sample size adequately powered to demonstrate non‐inferiority for this secondary outcome as well. Not downgraded. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD005437-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD005437-sec-0023"></div> <p>This is an update of a Cochrane review first published in the Cochrane Database of Systematic Reviews 2008, Issue 1 and updated in 2011 and 2013 (<a href="./references#CD005437-bbs2-0090" title="SudarsanamT , RupaliP , TharyanP , AbrahamOC , ThomasK . Pre‐admission antibiotics for suspected cases of meningococcal disease. Cochrane Database of Systematic Reviews2008, Issue 1. [DOI: 10.1002/14651858.CD005437.pub2] ">Sudarsanam 2008</a>; <a href="./references#CD005437-bbs2-0091" title="SudarsanamT , RupaliP , TharyanP , AbrahamOC , ThomasK . Pre‐admission antibiotics for suspected cases of meningococcal disease. Cochrane Database of Systematic Reviews2011, Issue 2. [DOI: 10.1002/14651858.CD005437.pub2] ">Sudarsanam 2011</a>; <a href="./references#CD005437-bbs2-0092" title="SudarsanamT , RupaliP , TharyanP , AbrahamOC , ThomasK . Pre‐admission antibiotics for suspected cases of meningococcal disease. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD005437.pub3] ">Sudarsanam 2013</a>). </p> <section id="CD005437-sec-0024"> <h3 class="title" id="CD005437-sec-0024">Description of the condition</h3> <p>Meningococcal disease is a contagious bacterial disease caused by <i>Neisseria meningitidis</i> . <i>N meningitidis</i> strains are classified primarily into serogroups based on the type of polysaccharide capsule expressed. While 13 serogroups have been described (A, B, C, D, 29E, H, I, K, L, Y, W‐135, X, and Z), most of the disease is caused by strains belonging to serogroups A, B, C, X, Y, and W‐135 (<a href="./references#CD005437-bbs2-0059" title="HillDJ ,  GriffithsNJ ,  BorodinaE ,  VirjiM . Cellular and molecular biology of Neisseria meningitidis colonization and invasive disease. Clinical Science (London)2010;9(118):547‐64. ">Hill 2010</a>). Serogroups B and C account for most of the cases in Europe and the Americas (<a href="./references#CD005437-bbs2-0033" title="Al‐TawfiqJA , ClarkTA , MemishZA . Meningococcal disease: the organism, clinical presentation, and worldwide epidemiology. Journal of Travel Medicine2010;17:3‐8. ">Al‐Tawfiq 2010</a>). Serogroups A and C are responsible for most of the cases in Asia and Africa (<a href="./references#CD005437-bbs2-0077" title="SchwartzB , MoorePS , BroomeCV . Global epidemiology of meningococcal disease. Clinical Microbiology Reviews1989;2(Suppl):118‐24. ">Schwartz 1989</a>; <a href="./references#CD005437-bbs2-0079" title="SinclairD , PreziosiMP , JohnJT , GreenwoodB . The epidemiology of meningococcal disease in India. Tropical Medicine and International Health2010;15:1421‐35. ">Sinclair 2010</a>). In the African 'meningitis belt' that extends from Ethiopia in the east to Senegal in the west, newer strains of serogroup A meningococcal disease have occurred in epidemic form that have posed a recurrent threat to public health, and rates of meningococcal disease in this region are several times higher than in high‐income countries (<a href="./references#CD005437-bbs2-0086" title="World Health Organization. Risk of epidemic meningitis in Africa: a cause for concern. Weekly Epidemiological Record2007;82:77‐88. ">WHO 2007</a>). </p> <p>In a systematic review of 132 studies published between 1980 to 2008 that reported on the incidence of disabling sequelae of bacterial meningitis in 18,183 adult and child survivors of bacterial meningitis, <i>Haemophilus influenzae</i> type b (Hib) was the most common cause of bacterial meningitis (35.5%), with pneumococcus accounting for 19.6%, meningococcus for 16.4% and other pathogens for 12% (<a href="./references#CD005437-bbs2-0046" title="EdmondK ,  ClarkA ,  KorczakVS ,  SandersonC ,  GriffithsUK ,  RudanI . Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta‐analysis. Lancet Infectious Diseases2010;10(5):317‐28. ">Edmond 2010</a>). However, the relative frequency of disease caused by <i>N meningitidis</i> has increased in recent years due to the widespread and successful use of an effective vaccine for <i>H influenzae</i> B and a conjugate vaccine for <i>Streptococcus pneumoniae</i> , leaving <i>N meningitidis</i> as the most common cause of bacterial meningitis, particularly in some parts of Africa where surveys indicate that <i>N meningitidis</i> was responsible for 60% to 70% of cases of meningitis (<a href="./references#CD005437-bbs2-0060" title="HsuHE ,  ShuttKA ,  MooreMR ,  BeallBW ,  BennettNM ,  CraigAS ,  etal . Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. New England Journal of Medicine2009;360(3):244‐56. ">Hsu 2009</a>; <a href="./references#CD005437-bbs2-0087" title="World Health Organization. Bacterial infections: meningococcal disease. www.who.int/vaccine_research/diseases/soa_bacterial/en/print.html 2010 (accessed prior to 2 June 2017). ">WHO 2010</a>). Meningococcal disease is most common in children (due to waning maternal antibody levels), adolescents, and young adults (<a href="./references#CD005437-bbs2-0087" title="World Health Organization. Bacterial infections: meningococcal disease. www.who.int/vaccine_research/diseases/soa_bacterial/en/print.html 2010 (accessed prior to 2 June 2017). ">WHO 2010</a>). </p> <p>Up to 5% to 10% of a population may be asymptomatic carriers of <i>N meningitidis</i>, in whom the bacteria are harmless commensals of the nasopharyngeal mucosa (<a href="./references#CD005437-bbs2-0087" title="World Health Organization. Bacterial infections: meningococcal disease. www.who.int/vaccine_research/diseases/soa_bacterial/en/print.html 2010 (accessed prior to 2 June 2017). ">WHO 2010</a>). Meningococcal disease is caused by a combination of bacterial virulence factors (particularly the ability to express capsules) and host susceptibility, including age, prior viral infection, overcrowding, smoking, co‐infections, and genetic polymorphisms (<a href="./references#CD005437-bbs2-0059" title="HillDJ ,  GriffithsNJ ,  BorodinaE ,  VirjiM . Cellular and molecular biology of Neisseria meningitidis colonization and invasive disease. Clinical Science (London)2010;9(118):547‐64. ">Hill 2010</a>; <a href="./references#CD005437-bbs2-0080" title="StephensDS ,  GreenwoodB ,  BrandtzaegP . Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet2007;369:2196‐201. ">Stephens 2007</a>). Meningococcal disease is spread by person‐to‐person contact through respiratory droplets from infected people. Meningococcal disease attack rates can be as high as 100 to 800 cases per 100,000 but individual communities have on occasion reported rates as high as 1000 per 100,000 (<a href="./references#CD005437-bbs2-0085" title="World Health Organization. Meningococcal meningitis. www.who.int/csr/disease/meningococcal/en/ 2004 (accessed prior to 2 June 2017). ">WHO 2004</a>). In 1996, the largest outbreak ever reported occurred in the meningitis belt, in which the total number of cases was over 250,000 with 25,000 reported deaths (<a href="./references#CD005437-bbs2-0073" title="RosensteinNE , PerkinsBA , StephensDS , PopovicT , HughesJM . Meningococcal disease. New England Journal of Medicine2001;344:1378‐88. ">Rosenstein 2001</a>). </p> <section id="CD005437-sec-0025"> <h4 class="title">Mortality</h4> <p>The onset of symptoms of meningococcal disease is sudden, and death can follow within hours (<a href="./references#CD005437-bbs2-0039" title="BorgJ , ChristieD , CoenPG , BooyR , VinerRM . Outcomes of meningococcal disease in adolescence: prospective, matched‐cohort study. Pediatrics2009;123:e502–9. [DOI: 10.1542/peds.2008‐0581] ">Borg 2009</a>; <a href="./references#CD005437-bbs2-0054" title="HackettSJ , GuiverM , MarshJ , SillsJA , ThomsonAPJ , KaczmarskiEB , et al. Meningococcal bacterial DNA load at presentation correlates with disease severity. Archives of Disease in Childhood2002;86:44‐6. ">Hackett 2002</a>; <a href="./references#CD005437-bbs2-0022" title="Perea‐MillaE , OlallaJ , Sanchez‐CantalejoE , MartosF , Matute‐CruzP , Carmona‐LopezG , et al. Pre‐hospital antibiotic treatment and mortality caused by invasive meningococcal disease, adjusting for indication bias. BMC Public Health2009;9:95. [Research Support, Non‐U.S. Gov't 19344518] ">Perea‐Milla 2009</a>). It is estimated that around 50,000 people, mostly children and young adults, die every year from among the approximately 500,000 cases of meningococcal disease reported annually (<a href="./references#CD005437-bbs2-0053" title="GranoffDM , HarrisonLH , BorrowR . Meningococcal vaccines. In: PlotkinSA , OrensteinWA , OffitP editor(s). Vaccines. 5th Edition. Philadelphia: Saunders Elsevier, 2008:399‐434. ">Granoff 2009</a>). Case fatality rates from invasive meningococcal disease are usually in the range of 10% to 15%, but mortality rates depend on the type and severity of invasive disease, and are greatest in people with meningococcaemia, fulminant septicaemia and shock (50% to 60%), followed by those with meningitis and associated septicaemia (up to 25%), and are lowest for meningitis without sepsis (less than 5%) (<a href="./references#CD005437-bbs2-0039" title="BorgJ , ChristieD , CoenPG , BooyR , VinerRM . Outcomes of meningococcal disease in adolescence: prospective, matched‐cohort study. Pediatrics2009;123:e502–9. [DOI: 10.1542/peds.2008‐0581] ">Borg 2009</a>; <a href="./references#CD005437-bbs2-0050" title="FergusonLE , HormannMD . Neisseria meningitidis: presentation, treatment and prevention. Journal of Pediatric Health Care2002;16:119‐24. ">Ferguson 2002</a>; <a href="./references#CD005437-bbs2-0059" title="HillDJ ,  GriffithsNJ ,  BorodinaE ,  VirjiM . Cellular and molecular biology of Neisseria meningitidis colonization and invasive disease. Clinical Science (London)2010;9(118):547‐64. ">Hill 2010</a>). </p> <p>Meningococcal disease differs from other gram‐negative bacterial infections by the release of lipopolysaccharide endotoxins and vesicles that cause rapidly progressing skin haemorrhage and necrosis, disseminated intravascular coagulation, and shock (<a href="./references#CD005437-bbs2-0042" title="BrandtzaegP ,  van DeurenM . Meningococcal infections at the start of the 21st century. Advances in Pediatrics2005;52:129‐62. ">Brandtzaeg 2005</a>). Other meningococcal virulence factors have been identified such as capsular polysaccharides (serogroups A, B, C, W‐135, Y, and X) and a number of surface‐expressed adhesive proteins, including factor H‐binding protein (fHbp), Opa, and Opc, that contribute to the ability to avoid innate immune responses and which aid adherence to mucosal surfaces (<a href="./references#CD005437-bbs2-0059" title="HillDJ ,  GriffithsNJ ,  BorodinaE ,  VirjiM . Cellular and molecular biology of Neisseria meningitidis colonization and invasive disease. Clinical Science (London)2010;9(118):547‐64. ">Hill 2010</a>; <a href="./references#CD005437-bbs2-0074" title="RouphaelNG ,  StephensDS . Neisseria meningitidis: biology, microbiology, and epidemiology. Methods in Molecular Biology2012;799:1‐20. ">Rouphael 2012</a>; <a href="./references#CD005437-bbs2-0075" title="SchneiderMC , ExleyRM , ChanH , FeaversI , KangYH , SimRB , et al. Functional significance of factor H binding to Neisseria meningitidis. Journal of Immunology2006;176:7566‐75. ">Schneider 2006</a>; <a href="./references#CD005437-bbs2-0080" title="StephensDS ,  GreenwoodB ,  BrandtzaegP . Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet2007;369:2196‐201. ">Stephens 2007</a>). Capsules of <i>N meningitidis</i> help with transmission and colonisation, and the ability to express and modify capsule is associated with its epidemic potential (<a href="./references#CD005437-bbs2-0080" title="StephensDS ,  GreenwoodB ,  BrandtzaegP . Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet2007;369:2196‐201. ">Stephens 2007</a>). </p> </section> <section id="CD005437-sec-0026"> <h4 class="title">Sequelae</h4> <p>There is significant resultant morbidity in 10% to 15% of survivors (<a href="./references#CD005437-bbs2-0035" title="BaraffLJ . Outcomes of bacterial meningitis in children: a meta‐analysis. Pediatric Infectious Disease Journal1993;12:389‐94. ">Baraff 1993</a>; <a href="./references#CD005437-bbs2-0039" title="BorgJ , ChristieD , CoenPG , BooyR , VinerRM . Outcomes of meningococcal disease in adolescence: prospective, matched‐cohort study. Pediatrics2009;123:e502–9. [DOI: 10.1542/peds.2008‐0581] ">Borg 2009</a>); from reports published between 1988 to 2008, the pooled median risk (and interquartile range) of developing at least one major sequela after hospital discharge in people with invasive meningococcal disease was 7.2% (4.3% to 11.2%) (<a href="./references#CD005437-bbs2-0046" title="EdmondK ,  ClarkA ,  KorczakVS ,  SandersonC ,  GriffithsUK ,  RudanI . Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta‐analysis. Lancet Infectious Diseases2010;10(5):317‐28. ">Edmond 2010</a>). The risk of major sequelae is greatest in the African and Southeast Asian regions and in low‐income countries (<a href="./references#CD005437-bbs2-0046" title="EdmondK ,  ClarkA ,  KorczakVS ,  SandersonC ,  GriffithsUK ,  RudanI . Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta‐analysis. Lancet Infectious Diseases2010;10(5):317‐28. ">Edmond 2010</a>; <a href="./references#CD005437-bbs2-0070" title="RamakrishnanM , UllandAJ , SteinhardtLC , MoïsiJC , WereF , LevineOS . Sequelae due to bacterial meningitis among African children: a systematic literature review. BMC Medicine2009;7:47. [DOI: 10.1186/1741‐7015‐7‐47] ">Ramakrishnan 2009</a>). Major sequelae are permanent neurological defects caused by pathophysiological inflammatory responses during infections. These involve increased blood‐brain barrier permeability; a large compartmentalised inflammatory response in the subarachnoid space, with pronounced increase in concentrations of tumour necrosis factor α (TNF‐α), interleukins, chemokines and other mediators; and increased resistance to the outflow of cerebrospinal fluid and oedema of the brain leading to elevated intracranial pressure and alterations in cerebral blood flow (<a href="./references#CD005437-bbs2-0059" title="HillDJ ,  GriffithsNJ ,  BorodinaE ,  VirjiM . Cellular and molecular biology of Neisseria meningitidis colonization and invasive disease. Clinical Science (London)2010;9(118):547‐64. ">Hill 2010</a>; <a href="./references#CD005437-bbs2-0080" title="StephensDS ,  GreenwoodB ,  BrandtzaegP . Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet2007;369:2196‐201. ">Stephens 2007</a>; <a href="./references#CD005437-bbs2-0081" title="TunkelAR , ScheldWM . Pathogenesis and pathophysiology of bacterial meningitis. Annual Reviews in Medicine1993;44:103‐20. ">Tunkel 1993</a>). The alteration in the permeability of the blood‐brain barrier is caused in part by inflammatory mediators such as matrix metalloproteinases (particularly MMP‐8), leading to disassembly of brain microvascular endothelial cell junction components and cell adhesion during meningococcal infection (<a href="./references#CD005437-bbs2-0076" title="Schubert‐UnkmeirA , KonradC , SlaninaH , CzapekF , HeblingS , FroschM . Neisseria meningitidis induces brain microvascular endothelial cell detachment from the matrix and cleavage of occludin: a role for MMP‐8. PLoS Pathogens2010;6(4):e1000874. [DOI: 10.1371/journal.ppat.1000874] ">Schubert‐Unkmeir 2010</a>). </p> <p>The resultant neurological deficits include hearing loss or deafness (most common), vision defects, speech disorders, amputation of limbs or digits and scarring of skin (due to extensive necrosis), hydrocephalus, mental retardation, spasticity, paralysis, and seizures, and present a long‐term and serious challenge for families with limited means to care for a disabled child, especially in resource‐poor settings (<a href="./references#CD005437-bbs2-0039" title="BorgJ , ChristieD , CoenPG , BooyR , VinerRM . Outcomes of meningococcal disease in adolescence: prospective, matched‐cohort study. Pediatrics2009;123:e502–9. [DOI: 10.1542/peds.2008‐0581] ">Borg 2009</a>; <a href="./references#CD005437-bbs2-0046" title="EdmondK ,  ClarkA ,  KorczakVS ,  SandersonC ,  GriffithsUK ,  RudanI . Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta‐analysis. Lancet Infectious Diseases2010;10(5):317‐28. ">Edmond 2010</a>; <a href="./references#CD005437-bbs2-0070" title="RamakrishnanM , UllandAJ , SteinhardtLC , MoïsiJC , WereF , LevineOS . Sequelae due to bacterial meningitis among African children: a systematic literature review. BMC Medicine2009;7:47. [DOI: 10.1186/1741‐7015‐7‐47] ">Ramakrishnan 2009</a>; <a href="./references#CD005437-bbs2-0085" title="World Health Organization. Meningococcal meningitis. www.who.int/csr/disease/meningococcal/en/ 2004 (accessed prior to 2 June 2017). ">WHO 2004</a>). Prevalence estimates of these sequelae do not account for the increased mortality or social drift further down the socio‐economic ladder in those with such disabilities, particularly in low‐income families and in resource‐poor settings, leading to underestimates of prevalence in surveys of postmeningitis sequelae (<a href="./references#CD005437-bbs2-0046" title="EdmondK ,  ClarkA ,  KorczakVS ,  SandersonC ,  GriffithsUK ,  RudanI . Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta‐analysis. Lancet Infectious Diseases2010;10(5):317‐28. ">Edmond 2010</a>). Even in high‐income countries, impaired cognitive functions and behavioural sequelae result in impairments in many areas of social, educational, occupational functioning and quality of life after bacterial meningitis (<a href="./references#CD005437-bbs2-0039" title="BorgJ , ChristieD , CoenPG , BooyR , VinerRM . Outcomes of meningococcal disease in adolescence: prospective, matched‐cohort study. Pediatrics2009;123:e502–9. [DOI: 10.1542/peds.2008‐0581] ">Borg 2009</a>). </p> <p>These estimates of the sequelae of invasive meningococcal disease also do not account for deaths that might have occurred before admission to hospital due to difficulties in establishing a clinical diagnosis, lack of clinical suspicion in areas not prone to epidemics, and delays in instituting effective treatment in areas with health systems unable to respond to these needs. Meningococcal disease has many clinical manifestations and is often difficult to differentiate from common, less serious illnesses. The infectious syndromes associated with meningococcaemia include meningitis, bacteraemia, pneumonia, epiglottitis, otitis, and focal diseases such as urethritis, conjunctivitis, arthritis, and pericarditis (<a href="./references#CD005437-bbs2-0080" title="StephensDS ,  GreenwoodB ,  BrandtzaegP . Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet2007;369:2196‐201. ">Stephens 2007</a>). Clinical suspicion of meningococcal infection may vary with the geographic locale of the study, the age group of the patients being studied (children or adults), and the criteria used for clinical diagnosis of meningococcal disease. Meningococcal disease is suspected when there is a characteristic skin rash, headache, weakness, fever, vomiting, and depressed sensorium, with or without evidence of sepsis (<a href="./references#CD005437-bbs2-0055" title="HahnéSJM , CharlettA , PurcellB , SamuelssonS , CamaroniI , EhrhardI , et al. Effectiveness of antibiotics given before admission in reducing mortality from meningococcal disease: systematic review. BMJ2006;332:1299‐303. ">Hahné 2006</a>; <a href="./references#CD005437-bbs2-0013" title="HarndenA , NinisN , ThompsonM , PereraR , LevinM , MantD , et al. Parenteral penicillin for children with meningococcal disease before hospital admission: case‐control study. BMJ2006;332(7553):1295‐8. [DOI: 10.1136/bmj.38789.723611.55] ">Harnden 2006</a>). </p> </section> <section id="CD005437-sec-0027"> <h4 class="title">Diagnosis</h4> <p>The definitive diagnosis of meningococcal infection requires isolation of <i>N meningitidis</i> (a gram‐negative intracellular diplococcus that ferments glucose and maltose) from a sterile body fluid such as blood, cerebrospinal fluid (CSF), or synovial, pleural, or pericardial fluids. In meningococcal meningitis, sterilisation of the CSF occurs rapidly (within two hours) after the instigation of antibiotics (<a href="./references#CD005437-bbs2-0061" title="KanegayeJT , SoliemanzadehP , BradleyJS . Lumbar puncture in pediatric bacterial meningitis: defining the time interval for recovery of cerebrospinal fluid pathogens after parenteral antibiotic pretreatment. Pediatrics2001;108:1169‐74. ">Kanegaye 2001</a>). Culture confirmation occurs in only a third of clinically diagnosed cases, yet meningococcal DNA can be detected in 88% of admission blood samples from the same patients, and molecular techniques using polymerase chain reaction (PCR) on the CSF are informative, even after starting antibiotics (<a href="./references#CD005437-bbs2-0054" title="HackettSJ , GuiverM , MarshJ , SillsJA , ThomsonAPJ , KaczmarskiEB , et al. Meningococcal bacterial DNA load at presentation correlates with disease severity. Archives of Disease in Childhood2002;86:44‐6. ">Hackett 2002</a>). Polymerase chain reaction of the blood is highly specific for <i>N meningitidis</i>, can be used for subgroup and serotyping, and may even be of prognostic significance; quantitative PCR reveals higher bacterial DNA load to be associated with greater severity of illness and greater risk of mortality (<a href="./references#CD005437-bbs2-0048" title="ElBashirH , LaundyM , BooyR . Diagnosis and treatment of bacterial meningitis. Archives of Disease in Childhood2003;88:615‐20. ">El Bashir 2003</a>; <a href="./references#CD005437-bbs2-0054" title="HackettSJ , GuiverM , MarshJ , SillsJA , ThomsonAPJ , KaczmarskiEB , et al. Meningococcal bacterial DNA load at presentation correlates with disease severity. Archives of Disease in Childhood2002;86:44‐6. ">Hackett 2002</a>). Polymerase chain reaction is more sensitive than culture, particularly in the context of pre‐admission treatment. The UK National Institute for Health and Care Excellence (NICE) guideline recommends that blood real‐time PCR should be done to confirm a diagnosis of meningococcal disease, and that CSF should also be submitted for PCR if the CSF culture is negative (<a href="./references#CD005437-bbs2-0065" title="National Collaborating Centre for Women’s and Children’s Health. Bacterial meningitis and meningococcal septicaemia: the management of bacterial meningitis and meningococcal septicaemia in children and young people younger than 16 years in primary and secondary care. NICE Clinical Guideline CG 102. www.nice.org.uk/CG102 (accessed prior to 2 June 2017). ">NICE 2010</a>). However, these techniques may not be readily available in resource‐poor settings. </p> </section> </section> <section id="CD005437-sec-0028"> <h3 class="title" id="CD005437-sec-0028">Description of the intervention</h3> <p>The use of antibiotics has dramatically reduced mortality due to meningococcal disease. Once diagnosis is confirmed, crystalline penicillin is commonly given intravenously every 4 to 6 hours for 7 to 10 days in individuals not at risk of anaphylaxis. Rates of bacterial penicillin resistance vary. In areas where penicillin resistance predominates, third‐generation cephalosporins such as cefotaxime and ceftriaxone are recommended by the Scottish Intercollegiate Guidelines Network (SIGN) guidelines, <a href="./references#CD005437-bbs2-0078" title="Scottish Intercollegiate Guidelines Network. Management of invasive meningococcal disease in children and young people. A National Clinical Guideline: 102. www.sign.ac.uk/pdf/sign102.pdf (accessed prior to 2 June 2017). ">SIGN 2008</a>, and the NICE guidelines, <a href="./references#CD005437-bbs2-0065" title="National Collaborating Centre for Women’s and Children’s Health. Bacterial meningitis and meningococcal septicaemia: the management of bacterial meningitis and meningococcal septicaemia in children and young people younger than 16 years in primary and secondary care. NICE Clinical Guideline CG 102. www.nice.org.uk/CG102 (accessed prior to 2 June 2017). ">NICE 2010</a>, respectively. However, quinolones are not approved for routine paediatric usage and ceftriaxone requires parenteral administration (<a href="./references#CD005437-bbs2-0051" title="GirgisN , SultanY , FrenckRWJr , El‐GendyA , FaridZ , MateczunA . Azithromycin compared with rifampin for eradication of nasopharyngeal colonization by Neisseria meningitidis. Pediatric Infectious Disease Journal1998;17:816‐9. ">Girgis 1998</a>). Sulphonamides are now rarely used, as intermediate resistance to these drugs is reported in some areas (<a href="./references#CD005437-bbs2-0047" title="EickhoffTC , FinlandM . Changing susceptibility of meningococci to antimicrobial agents. New England Journal of Medicine1965;272:395‐8. ">Eickhoff 1965</a>). Oral macrolide and beta‐lactam antibiotics are also effective in treating invasive meningococcal disease and averting mortality, though their routine use in suspected cases of invasive meningococcal disease may depend on 'indication bias' (bias in initiating oral versus parenteral or no antibiotics due to perceptions of mild to moderate, as opposed to severe, illness severity) (<a href="./references#CD005437-bbs2-0022" title="Perea‐MillaE , OlallaJ , Sanchez‐CantalejoE , MartosF , Matute‐CruzP , Carmona‐LopezG , et al. Pre‐hospital antibiotic treatment and mortality caused by invasive meningococcal disease, adjusting for indication bias. BMC Public Health2009;9:95. [Research Support, Non‐U.S. Gov't 19344518] ">Perea‐Milla 2009</a>). A Cochrane review studied osmotic agents for bacterial meningitis and found no benefit (<a href="./references#CD005437-bbs2-0082" title="WallECB , AjdukiewiczKMB , HeydermanRS , GarnerP . Osmotic therapies added to antibiotics for acute bacterial meningitis. Cochrane Database of Systematic Reviews2013, Issue 3. [DOI: 10.1002/14651858.CD008806.pub2] ">Wall 2013</a>). </p> <p>The efficacy of short courses of ceftriaxone and oily chloramphenicol has been demonstrated in the treatment of meningococcal meningitis in adults (<a href="./references#CD005437-bbs2-0049" title="elFilaliM , NoumM , ChakibA , ZahraouiM , HimmichH . Ceftriaxone versus penicillin G in the short term treatment of meningococcal meningitis in adults. European Journal of Clinical Microbiology &amp; Infectious Diseases1993;12:766‐8. ">El Filali 1993</a>). In one epidemic, a single intramuscular injection of an oily suspension of long‐acting chloramphenicol proved as effective as a five‐day course of crystalline penicillin (<a href="./references#CD005437-bbs2-0084" title="WHO Working Group. Control of Epidemic Meningococcal Diseases: WHO Practical Guidelines. Lyon, France: Edition Foundation Marcel Merieux, 1995. ">WHO 1995</a>). Chloramphenicol is bactericidal for <i>N meningitidis</i> and penetrates the blood‐brain barrier more effectively than beta‐lactam antibiotics (<a href="./references#CD005437-bbs2-0021" title="PecoulB , VaraineF , KeitaM , SogaG , DjiboA , SoulaG , et al. Long‐acting chloramphenicol versus intravenous ampicillin for treatment of bacterial meningitis. Lancet1991;338(8771):862‐6. [CN‐00078644] ">Pecoul 1991</a>). Intravenous cefotaxime plus either ampicillin or amoxacillin is recommended in children under three years of age (<a href="./references#CD005437-bbs2-0065" title="National Collaborating Centre for Women’s and Children’s Health. Bacterial meningitis and meningococcal septicaemia: the management of bacterial meningitis and meningococcal septicaemia in children and young people younger than 16 years in primary and secondary care. NICE Clinical Guideline CG 102. www.nice.org.uk/CG102 (accessed prior to 2 June 2017). ">NICE 2010</a>). Cefotaxime or ceftriaxone, often combined with vancomycin, are also used in high‐income countries until the causative agent has been identified (<a href="./references#CD005437-bbs2-0080" title="StephensDS ,  GreenwoodB ,  BrandtzaegP . Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet2007;369:2196‐201. ">Stephens 2007</a>). A systematic review did not reveal important differences between third‐generation cephalosporins or conventional antibiotics in averting death or deafness in people with bacterial meningitis (<a href="./references#CD005437-bbs2-0069" title="PrasadK , KumarA , SinghalT , GuptaPK . Third generation cephalosporins versus conventional antibiotics for treating acute bacterial meningitis. Cochrane Database of Systematic Reviews2011, Issue 10. [DOI: 10.1002/14651858.CD001832.pub3] ">Prasad 2011</a>) </p> <p>A recent Cochrane review found that rifampicin, ciprofloxacin, ceftriaxone, or penicillin are effective for prophylaxis, with rifampicin resistance being an issue, as mentioned above (<a href="./references#CD005437-bbs2-0088" title="Zalmanovici TrestioreanuA , FraserA , Gafter‐GviliA , PaulM , LeiboviciL . Antibiotics for preventing meningococcal infections. Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD004785.pub5] ">Zalmanovici 2013</a>). </p> </section> <section id="CD005437-sec-0029"> <h3 class="title" id="CD005437-sec-0029">How the intervention might work</h3> <p>The aim of pre‐admission antibiotic therapy is to reduce the risk of serious disease by preventing delays in starting therapy. This delay may occur if confirmation of meningococcus is sought before initiation of therapy. It is believed that if treatment is begun early, the associated severe complications and mortality may be avoided or minimised by preventing or reducing the effects of the systemic inflammatory response of the body, including reduced inflammatory cytokines and chemokines, and endotoxin production; and also lead to a reduction in bacterial proliferation (<a href="./references#CD005437-bbs2-0041" title="BrandtzaegP ,  KierulfP ,  GaustadP ,  SkulbergA ,  BruunJN ,  HalvorsenS ,  etal . Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. Journal of Infectious Diseases1989;159(2):195‐204. ">Brandtzaeg 1989</a>; <a href="./references#CD005437-bbs2-0061" title="KanegayeJT , SoliemanzadehP , BradleyJS . Lumbar puncture in pediatric bacterial meningitis: defining the time interval for recovery of cerebrospinal fluid pathogens after parenteral antibiotic pretreatment. Pediatrics2001;108:1169‐74. ">Kanegaye 2001</a>; <a href="./references#CD005437-bbs2-0083" title="WangVJ ,  MalleyR ,  FleisherGR ,  InkelisSH ,  KuppermannN . Antibiotic treatment of children with unsuspected meningococcal disease. Archives of Pediatrics and Adolescent Medicine2000;154(6):556‐60. ">Wang 2000</a>). Preventing meningococcal shock is dependent on reducing endotoxin levels and meningococcal bacterial load (<a href="./references#CD005437-bbs2-0054" title="HackettSJ , GuiverM , MarshJ , SillsJA , ThomsonAPJ , KaczmarskiEB , et al. Meningococcal bacterial DNA load at presentation correlates with disease severity. Archives of Disease in Childhood2002;86:44‐6. ">Hackett 2002</a>), and given that meningococcaemia is a rapidly progressive disease, with an estimated doubling time of meningococci of 30 to 40 minutes (<a href="./references#CD005437-bbs2-0080" title="StephensDS ,  GreenwoodB ,  BrandtzaegP . Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet2007;369:2196‐201. ">Stephens 2007</a>), the time available for early administration of antibiotics is limited. </p> <p>With this in mind, the concept of empiric antibiotic use based on clinical suspicion, before a confirmed bacteriological diagnosis is made, or the 'pre‐admission' use of antibiotics prescribed or administered by the doctor in first contact with the patient, has been found to be effective in reducing mortality and complications due to meningococcal disease in observational studies (<a href="./references#CD005437-bbs2-0055" title="HahnéSJM , CharlettA , PurcellB , SamuelssonS , CamaroniI , EhrhardI , et al. Effectiveness of antibiotics given before admission in reducing mortality from meningococcal disease: systematic review. BMJ2006;332:1299‐303. ">Hahné 2006</a>; <a href="./references#CD005437-bbs2-0022" title="Perea‐MillaE , OlallaJ , Sanchez‐CantalejoE , MartosF , Matute‐CruzP , Carmona‐LopezG , et al. Pre‐hospital antibiotic treatment and mortality caused by invasive meningococcal disease, adjusting for indication bias. BMC Public Health2009;9:95. [Research Support, Non‐U.S. Gov't 19344518] ">Perea‐Milla 2009</a>; <a href="./references#CD005437-bbs2-0030" title="StrangJR , PughEJ . Meningococcal infections: reducing the case fatality rate by giving penicillin before admission to hospital. BMJ1992;305(6846):141‐3. ">Strang 1992</a>; <a href="./references#CD005437-bbs2-0083" title="WangVJ ,  MalleyR ,  FleisherGR ,  InkelisSH ,  KuppermannN . Antibiotic treatment of children with unsuspected meningococcal disease. Archives of Pediatrics and Adolescent Medicine2000;154(6):556‐60. ">Wang 2000</a>).  </p> </section> <section id="CD005437-sec-0030"> <h3 class="title" id="CD005437-sec-0030">Why it is important to do this review</h3> <p>Standard policy in many countries (<a href="./references#CD005437-bbs2-0055" title="HahnéSJM , CharlettA , PurcellB , SamuelssonS , CamaroniI , EhrhardI , et al. Effectiveness of antibiotics given before admission in reducing mortality from meningococcal disease: systematic review. BMJ2006;332:1299‐303. ">Hahné 2006</a>), backed by recommendations from professional associations, mandates the initiation of antibiotics, particularly penicillin, once criteria for bacterial meningitis are met. Some policies contend that initiating antibiotic therapy requires the prior collection of CSF for bacterial confirmation or the use of PCR of the CSF, though there is a lack of consensus on the need for confirmation of the diagnosis before starting antibiotics (<a href="./references#CD005437-bbs2-0055" title="HahnéSJM , CharlettA , PurcellB , SamuelssonS , CamaroniI , EhrhardI , et al. Effectiveness of antibiotics given before admission in reducing mortality from meningococcal disease: systematic review. BMJ2006;332:1299‐303. ">Hahné 2006</a>). The NICE guideline states that children with suspected meningitis and meningococcal disease should have a lumbar puncture unless specifically contraindicated (<a href="./references#CD005437-bbs2-0065" title="National Collaborating Centre for Women’s and Children’s Health. Bacterial meningitis and meningococcal septicaemia: the management of bacterial meningitis and meningococcal septicaemia in children and young people younger than 16 years in primary and secondary care. NICE Clinical Guideline CG 102. www.nice.org.uk/CG102 (accessed prior to 2 June 2017). ">NICE 2010</a>). </p> <p>However, it is not clear whether treating all suspected cases is associated with improved outcomes, since the effects of confounding are difficult to interpret in the observational studies supporting this view (<a href="./references#CD005437-bbs2-0055" title="HahnéSJM , CharlettA , PurcellB , SamuelssonS , CamaroniI , EhrhardI , et al. Effectiveness of antibiotics given before admission in reducing mortality from meningococcal disease: systematic review. BMJ2006;332:1299‐303. ">Hahné 2006</a>; <a href="./references#CD005437-bbs2-0013" title="HarndenA , NinisN , ThompsonM , PereraR , LevinM , MantD , et al. Parenteral penicillin for children with meningococcal disease before hospital admission: case‐control study. BMJ2006;332(7553):1295‐8. [DOI: 10.1136/bmj.38789.723611.55] ">Harnden 2006</a>; <a href="./references#CD005437-bbs2-0062" title="KeeleyD . Parenteral penicillin before admission to hospital for meningitis. BMJ2006;332:1283‐4. ">Keeley 2006</a>; <a href="./references#CD005437-bbs2-0029" title="SorensenHT , NielsenGL , SchonheyderHC , SteffensenFH , HansenI , SabroeS , et al. Outcome of pre‐hospital antibiotic treatment of meningococcal disease. Journal of Clinical Epidemiology1998;51(9):717‐21. [MEDLINE: 1998321631] ">Sorensen 1998</a>). </p> <p>In previous versions of this review we identified no trials comparing pre‐admission antibiotics to no antibiotic prior to confirmation of meningococcal meningitis (<a href="./references#CD005437-bbs2-0090" title="SudarsanamT , RupaliP , TharyanP , AbrahamOC , ThomasK . Pre‐admission antibiotics for suspected cases of meningococcal disease. Cochrane Database of Systematic Reviews2008, Issue 1. [DOI: 10.1002/14651858.CD005437.pub2] ">Sudarsanam 2008</a>; <a href="./references#CD005437-bbs2-0091" title="SudarsanamT , RupaliP , TharyanP , AbrahamOC , ThomasK . Pre‐admission antibiotics for suspected cases of meningococcal disease. Cochrane Database of Systematic Reviews2011, Issue 2. [DOI: 10.1002/14651858.CD005437.pub2] ">Sudarsanam 2011</a>; <a href="./references#CD005437-bbs2-0092" title="SudarsanamT , RupaliP , TharyanP , AbrahamOC , ThomasK . Pre‐admission antibiotics for suspected cases of meningococcal disease. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD005437.pub3] ">Sudarsanam 2013</a>). We identified one trial that demonstrated the non‐inferiority of a single dose of intramuscular ceftriaxone versus a single dose of intramuscular long‐acting (oily) chloramphenicol in reducing serious outcomes. </p> <p>This review update sought additional trials assessing the use of antibiotic therapy in suspected cases of meningococcal disease, and those that compared different classes of antibiotics used for this infection before confirmation of the diagnosis. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD005437-sec-0031" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD005437-sec-0031"></div> <p>To study the effectiveness and safety of pre‐admission antibiotics versus no pre‐admission antibiotics or placebo, and different pre‐admission antibiotic regimens in decreasing mortality, clinical failure and morbidity in people suspected of meningococcal disease. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD005437-sec-0032" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD005437-sec-0032"></div> <section id="CD005437-sec-0033"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD005437-sec-0034"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs) or quasi‐RCTs.</p> </section> <section id="CD005437-sec-0035"> <h4 class="title">Types of participants</h4> <p>People of all ages who were suspected to have meningococcal infection in whom antibiotics were started presumptively before confirmation of the diagnosis, or transfer to hospital. </p> <p>Participants of trials that looked at treatment of 'meningitis' or 'bacterial meningitis', where it may not have been possible to distinguish the results that applied to meningococcal disease, were treated as having 'suspected meningococcal infection'. </p> </section> <section id="CD005437-sec-0036"> <h4 class="title">Types of interventions</h4> <p> <ol id="CD005437-list-0001"> <li> <p>Antibiotic treatment versus placebo or no intervention.</p> </li> <li> <p>Any antibiotic versus another antibiotic from a different class.</p> </li> <li> <p>Combinations of antibiotics versus another antibiotic or combinations of other antibiotics.</p> </li> </ol> </p> <p>Pre‐admission antibiotic treatment refers to the use of antibiotic treatment for an initial dose, or doses, by any route before the diagnosis is confirmed. </p> </section> <section id="CD005437-sec-0037"> <h4 class="title">Types of outcome measures</h4> <section id="CD005437-sec-0038"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD005437-list-0002"> <li> <p>Mortality: death before reaching hospital, in hospital, or within a month of discharge or leaving the hospital. </p> </li> <li> <p>Lack of clinical improvement: as defined by individual trials.</p> </li> <li> <p>Morbidity: persistent neurological defects in the form of vision and hearing loss, speech disorders, persistent cognitive or intellectual impairment, and paralysis, or any other recorded persistent neurological defects. </p> </li> </ol> </p> </section> <section id="CD005437-sec-0039"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD005437-list-0003"> <li> <p>Burden of disease: on the family, individual, or caregiver; as reported using a validated scale or measure. </p> </li> <li> <p>Adverse events: antibiotic‐related clinical adverse effects.</p> </li> <li> <p>Economic costs of the intervention: if reported as done alongside the conduct of included RCTs. </p> </li> </ol> </p> <p>We grouped the primary outcome of morbidity and all secondary outcomes by time. We defined 'short term' as less than six weeks; 'medium term' as six weeks to six months; and 'long term' as more than six months after the onset of symptoms subsequently confirmed to be due to meningococcal meningitis. </p> </section> </section> </section> <section id="CD005437-sec-0040"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD005437-sec-0041"> <h4 class="title">Electronic searches</h4> <p>For this update we searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 12), part of the Cochrane Library, <a href="http://www.cochranelibrary.com/" target="_blank">www.cochranelibrary.com/</a> (accessed 6 January 2017), which includes the Cochrane Acute Respiratory Infections Group's Specialised Register, MEDLINE Ovid (1966 to 6 January 2017), Embase.com (1980 to 6 January 2017), Web of Science (1985 to 6 January 2017), and LILACS (Latin American and Caribbean Health Sciences Literature) (1982 to 6 January 2017). We did not update the previous CAB Abstracts search (1985 to June 2015) in January 2017 due to lack of institutional access to that database. See <a href="./appendices#CD005437-sec-0096">Appendix 1</a> for details of previous searches. </p> <p>We used the search strategy in <a href="./appendices#CD005437-sec-0097">Appendix 2</a> to search MEDLINE and CENTRAL. We combined the MEDLINE search with the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE: sensitivity‐maximising version (2008 revision); Ovid format (<a href="./references#CD005437-bbs2-0063" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Lefebvre 2011</a>). We adapted the search strategy for Embase.com (<a href="./appendices#CD005437-sec-0098">Appendix 3</a>), Web of Science (<a href="./appendices#CD005437-sec-0099">Appendix 4</a>), LILACS (<a href="./appendices#CD005437-sec-0100">Appendix 5</a>), and CAB Abstracts (<a href="./appendices#CD005437-sec-0101">Appendix 6</a>). We applied no language or publication restrictions. </p> <p>The PRISMA figure summarises this process (<a href="#CD005437-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD005437-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD005437-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005437.pub4/media/CDSR/CD005437/image_n/nCD005437-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD005437-sec-0042"> <h4 class="title">Searching other resources</h4> <p>We also searched the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (<a href="http://apps.who.int/trialsearch/default.aspx" target="_blank">apps.who.int/trialsearch/default.aspx</a>), ClinicalTrials.gov (<a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>), and the ISRCTN register (<a href="http://www.controlled-trials.com/isrctn/search.html" target="_blank">www.controlled‐trials.com/isrctn/search.html</a>) for ongoing and completed clinical trials, using the search terms 'meningococcal' AND 'meningitis' (searched 13 February 2017). We searched the references of all identified studies, as well as major reviews, for additional studies. </p> </section> </section> <section id="CD005437-sec-0043"> <h3 class="title" id="CD005437-sec-0043">Data collection and analysis</h3> <section id="CD005437-sec-0044"> <h4 class="title">Selection of studies</h4> <p>Two review authors (TS, PR) independently inspected each reference identified by the electronic searches and applied the inclusion criteria. We retrieved the full articles of trials that were deemed potentially relevant and in cases of disagreement. Two review authors (TS, PR) independently inspected the full articles to determine if they met the inclusion criteria, consulting a third review author (PT) when disagreements persisted. We discarded reports that were clearly irrelevant. We recorded studies on pre‐admission antibiotics that did not fulfil the inclusion criteria along with the reasons for their exclusion in the <a href="./references#CD005437-sec-0115" title="">Characteristics of excluded studies</a> table. </p> </section> <section id="CD005437-sec-0045"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (TS, PR) independently extracted data. We discussed the data extraction, documented decisions and, where necessary, contacted the trial authors for clarification. A third review author (PT) independently checked the extracted data. </p> <p>We extracted, checked, and recorded the following data.</p> <p> <ol id="CD005437-list-0004"> <li> <p>Characteristics of trials: design, date, location, and setting of trial; publication status; sponsor of trial (specified, known or unknown); duration of follow‐up. </p> </li> <li> <p>Characteristics of participants: age; number of participants in each group; gender, setting, location. </p> </li> <li> <p>Characteristics of interventions: type of antibiotics; dose, mode of administration, schedule; length of treatment and follow‐up. </p> </li> <li> <p>Characteristics of outcome measures: we recorded data for events listed in the <a href="#CD005437-sec-0037">Types of outcome measures</a> section for each intervention arm. </p> </li> <li> <p>For economic analyses, key items of resource use (costs) and outcomes (beneficial and adverse), cost per unit of effort, quality adjusted life years (QALYs), or cost‐benefit analyses (resource inputs and effects of alternative interventions expressed in monetary units), if detailed in trial reports. If available, we would have recorded the following: analytic perspective adopted (for example, societal; national/subnational; third‐party payer; institution); time horizon for both costs (resource use) and effects (beneficial and adverse effects); and sources of resource use, unit costs, and (if applicable) effects and benefit valuation data (<a href="./references#CD005437-bbs2-0043" title="The Campbell Collaboration. The Campbell Collaboration Economics Methods Policy Brief Version 1.0 April 2008. www.campbellcollaboration.org/artman2/uploads/1/Economic_Methods_Policy_Brief.pdf 2009 (accessed 21 July 2009). ">Campbell Collaboration 2008</a>). </p> </li> </ol> </p> </section> <section id="CD005437-sec-0046"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (TS, PR) independently assessed the included studies for risk of bias using Cochrane's 'Risk of bias' assessment tool on the following six domains: sequence generation, allocation concealment, blinding or masking, incomplete outcome data, selective outcome reporting, and other biases (<a href="./references#CD005437-bbs2-0057" title="HigginsJP , Altman , DG , Sterne JAC on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In: Higgins JT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). A third review author (PT) checked this assessment. </p> <p>We judged each of these six domains as low risk of bias, high risk of bias, or unclear risk of bias, the last when due to lack of information in the report or after contacting the trial authors we were unable to make a reliable assessment. We used the criteria summarised in Table 8.5.c of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> to make judgements (<a href="./references#CD005437-bbs2-0057" title="HigginsJP , Altman , DG , Sterne JAC on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In: Higgins JT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>), and recorded these assessments in the standard 'Risk of bias' tables in Review Manager 5 (<a href="./references#CD005437-bbs2-0071" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We presented these evaluations in the 'Risk of bias' summary figure (<a href="#CD005437-fig-0002">Figure 2</a>) and discussed them further in the <a href="#CD005437-sec-0061">Risk of bias in included studies</a> section. We incorporated these judgements in assessing limitations in study design for critical and important outcomes in the <a href="./full#CD005437-tbl-0001">summary of findings Table for the main comparison</a>. </p> <div class="figure" id="CD005437-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for Nathan 2005." data-id="CD005437-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005437.pub4/media/CDSR/CD005437/image_n/nCD005437-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for <a href="./references#CD005437-bbs2-0001" title="NathanN , BorelT , DjiboA , EvansD , DjiboS , CortyJF , et al. Ceftriaxone as effective as long‐acting chloramphenicol in short‐course treatment of meningococcal meningitis during epidemics: a randomised non‐inferiority study. Lancet2005;366:308‐13. ">Nathan 2005</a>. </p> </div> </div> </div> </section> <section id="CD005437-sec-0047"> <h4 class="title">Measures of treatment effect</h4> <p>Only one study fulfilled the inclusion criteria, and we analysed dichotomous data from this trial by calculating the risk ratio (RR) and 95% confidence intervals (CI) for each outcome. </p> </section> <section id="CD005437-sec-0048"> <h4 class="title">Unit of analysis issues</h4> <p>No non‐standard designs were used in the single included trial.</p> <p>Had more trials been included in this review and had the included trials randomised participants by clusters, such as villages or health centres, and had the results been adjusted for clustering, we would have combined the adjusted measures of effects of these cluster‐randomised trials. If results had not been adjusted for clustering, we would have attempted to adjust the results for clustering, by multiplying the standard errors of the estimates by the square root of the design effect (where the design effect is calculated as D<sub>Eff</sub> = 1 + (M ‐ 1) ICC, where M is the average cluster size and ICC is the intracluster coefficient). If this was not possible, we would not have combined the trials in a meta‐analysis, but would have presented the results in an Additional table. </p> <p>If time‐to‐event outcomes had been reported, we would have extracted the estimates of the log hazard ratio and its standard error. If standard errors were unavailable, we would have extracted alternative statistics such as confidence intervals or P values. </p> </section> <section id="CD005437-sec-0049"> <h4 class="title">Dealing with missing data</h4> <p>We contacted trial authors for missing data. We planned to exclude any trial with more than 20% unexplained dropouts in any arm. However, the included trial reported reasons for dropouts, and the trial authors provided supplementary information. The data were adequately presented, and the report provided intention‐to‐treat (ITT) and per‐protocol analyses data, as well as a participant flow diagram in a sufficiently detailed manner as to facilitate data retrieval. </p> <p>We extracted data to allow an ITT analysis in which all randomised participants were analysed in the groups to which they were originally assigned. If there was a discrepancy in the number randomised and the numbers analysed in each treatment group, we calculated the percentage loss to follow‐up in each group and reported this information. If unexplained dropouts exceeded 10% in either group, we would have assigned the worst outcome to those lost to follow‐up for dichotomous outcomes (except for mortality) and assessed the impact of this in sensitivity analyses with the results of completers. </p> <p>For continuous outcomes, if provided and where possible, we would have calculated missing standard deviations from other available data such as standard errors (<a href="./references#CD005437-bbs2-0058" title="HigginsJP , DeeksJJ , editor(s) . Chapter 7: Selecting studies and collecting data. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011b</a>). However, we would not have imputed missing values in order to present these in the analyses. We would not have made any assumptions about loss to follow‐up for continuous data and would have analysed results for those participants who completed the trial. </p> </section> <section id="CD005437-sec-0050"> <h4 class="title">Assessment of heterogeneity</h4> <p>Had we included additional trials, we would have supplemented the inspection of the graphical display of results for non‐overlapping CIs among individual trials with the Mantel‐Haenszel Chi<sup>2</sup> test of heterogeneity. Since this test has low power to detect heterogeneity, we would have interpreted a significance level of less than 0.10 as evidence of heterogeneity. </p> <p>In addition, we would have quantified inconsistency across studies and its impact on the meta‐analysis by examining the value of the I<sup>2</sup> statistic to estimate the percentage of variability due to intertrial variability rather than random error. We would have interpreted an I<sup>2</sup> statistic of 50% or greater as indicating substantial levels of heterogeneity (<a href="./references#CD005437-bbs2-0056" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>). </p> </section> <section id="CD005437-sec-0051"> <h4 class="title">Assessment of reporting biases</h4> <p>Had there been sufficient studies (at least 10), we would have used a funnel plot of treatment effect against its standard error (as a measure of study size) to assess possible publication bias or small‐study effects. </p> </section> <section id="CD005437-sec-0052"> <h4 class="title">Data synthesis</h4> <p>Since only one trial fulfilled the inclusion criteria, we presented the RR and 95% Cl for the prespecified outcomes from this trial. </p> <p>Had there been more included trials, we would have pooled data for dichotomous outcomes using the inverse variance fixed‐effect model; if heterogeneity was deemed substantial, we would have used the random‐effects model. </p> <p>For continuous data such as caregiver burden or quality of life assessments measured in similar ways, we had planned to calculate the difference in means weighted by the inverse of the variance. We would have used the standardised mean difference to pool results if continuous outcome data assessing similar outcomes were measured in different ways. If the distribution of the outcome data was significantly skewed and the studies were small, we would have looked for a suitable normalisation method or requested more appropriate summaries of the data from the investigators. </p> <section id="CD005437-sec-0053"> <h5 class="title">GRADE and 'Summary of findings' table</h5> <p>We created a 'Summary of findings' table using the following outcomes: death in all participants with a short‐term follow‐up of 72 hours; death in confirmed cases of meningococcal meningitis; clinical failure in confirmed cases of meningococcal meningitis; neurological sequelae in all participants with a short‐term follow‐up of 72 hours; neurological sequelae in confirmed cases of meningococcal meningitis; and adverse events with a short‐term follow‐up of 72 hours. We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the quality of a body of evidence as it relates to the studies that contribute data to the meta‐analyses for the prespecified outcomes (<a href="./references#CD005437-bbs2-0034" title="AtkinsD , BestD , BrissPA , EcclesM , Falck‐YtterY , FlottorpS , et al. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ2004;328(7454):1490. ">Atkins 2004</a>). We used methods and recommendations described in Section 8.5 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD005437-bbs2-0057" title="HigginsJP , Altman , DG , Sterne JAC on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In: Higgins JT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>), employing GRADEpro GDT software (<a href="./references#CD005437-bbs2-0052" title="GRADE Working Group, McMaster University. GRADEpro GDT [GRADEpro GDT]. Hamilton (ON): GRADE Working Group, McMaster University, 2014. ">GRADEpro GDT 2014</a>). We justified all decisions to down‐ or upgrade the quality of studies using footnotes, and we made comments to aid the reader's understanding of the review where necessary. </p> </section> </section> <section id="CD005437-sec-0054"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We would have evaluated the pooled results from additional studies that used comparable participants, interventions, methods, and outcomes for evidence of significant heterogeneity that would have precluded a reliable interpretation of a common 'average' effect of the combined effects of the interventions. </p> <p>Had the I<sup>2</sup> statistic exceeded 75% with no explanation for this inconsistency (see below) in the effects of interventions across trials, we would have presented the results in a forest plot without pooling data. </p> <p>We anticipated between‐trial variations in the following situations and therefore intended to perform subgroup analyses when: </p> <p> <ol id="CD005437-list-0005"> <li> <p>baseline risk levels (severity of infection) differed between trials;</p> </li> <li> <p>trials presented results for people with suspected versus confirmed meningococcal meningitis; analysing the results separately allows for evaluating the effects of differences in these proportions across trials and the effects of different indices of suspicion for bacterial meningitis during and outside of epidemic settings; </p> </li> <li> <p>trials differed by levels of health service delivery (low‐income versus moderate‐ to high‐income settings); </p> </li> <li> <p>trials differed by duration of follow‐up (short term (&lt; six weeks); medium term (six weeks to six months); long term (&gt; than six months). </p> </li> </ol> </p> <p>If subgroups appeared to differ in the effects of interventions, as evident by non‐overlapping Cls, we would have performed formal tests for subgroup differences using the methods described in <a href="./references#CD005437-bbs2-0058" title="HigginsJP , DeeksJJ , editor(s) . Chapter 7: Selecting studies and collecting data. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011b</a>, which are possible in Review Manager 5 when the inverse variance method is used to pool dichotomous data (<a href="./references#CD005437-bbs2-0071" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> </section> <section id="CD005437-sec-0055"> <h4 class="title">Sensitivity analysis</h4> <p>We had also planned to perform sensitivity analyses to assess the robustness of our findings to different aspects of risk of bias among included trials and to evaluate the assumptions made in ITT and completer analyses. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD005437-sec-0056" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD005437-sec-0056"></div> <section id="CD005437-sec-0057"> <h3 class="title">Description of studies</h3> <section id="CD005437-sec-0058"> <h4 class="title">Results of the search</h4> <p>Our original review retrieved 136 reports (<a href="./references#CD005437-bbs2-0090" title="SudarsanamT , RupaliP , TharyanP , AbrahamOC , ThomasK . Pre‐admission antibiotics for suspected cases of meningococcal disease. Cochrane Database of Systematic Reviews2008, Issue 1. [DOI: 10.1002/14651858.CD005437.pub2] ">Sudarsanam 2008</a>). Of these, we obtained hard copies of 30 potentially eligible trials. Only <a href="./references#CD005437-bbs2-0001" title="NathanN , BorelT , DjiboA , EvansD , DjiboS , CortyJF , et al. Ceftriaxone as effective as long‐acting chloramphenicol in short‐course treatment of meningococcal meningitis during epidemics: a randomised non‐inferiority study. Lancet2005;366:308‐13. ">Nathan 2005</a> met the inclusion criteria. The search also retrieved a systematic review on the same topic that was published while the first version of this review was underway (<a href="./references#CD005437-bbs2-0055" title="HahnéSJM , CharlettA , PurcellB , SamuelssonS , CamaroniI , EhrhardI , et al. Effectiveness of antibiotics given before admission in reducing mortality from meningococcal disease: systematic review. BMJ2006;332:1299‐303. ">Hahné 2006</a>). <a href="./references#CD005437-bbs2-0055" title="HahnéSJM , CharlettA , PurcellB , SamuelssonS , CamaroniI , EhrhardI , et al. Effectiveness of antibiotics given before admission in reducing mortality from meningococcal disease: systematic review. BMJ2006;332:1299‐303. ">Hahné 2006</a> included 14 cohort studies but did not include any RCTs. Another review of observational studies looked at seven trials and also did not include any RCTs (<a href="./references#CD005437-bbs2-0016" title="LeclercF , NoizetO , DorkenooA , CremerR , LeteurtreS , SadikA , et al. Treatment of meningococcal purpura fulminans. Archives de Pediatrie2001;8(Suppl 4):667‐88. [MEDLINE: 2001324586] ">Leclerc 2001</a>). </p> <p>An updated search in June 2010 retrieved 46 records, only one of which was relevant to this review (<a href="./references#CD005437-bbs2-0091" title="SudarsanamT , RupaliP , TharyanP , AbrahamOC , ThomasK . Pre‐admission antibiotics for suspected cases of meningococcal disease. Cochrane Database of Systematic Reviews2011, Issue 2. [DOI: 10.1002/14651858.CD005437.pub2] ">Sudarsanam 2011</a>). It was a retrospective analysis that controlled for the effects of indication bias in prescribing antibiotics by using propensity scores to evaluate the effects of pre‐admission antibiotics in preventing deaths due to meningococcal disease during an epidemic in Spain (<a href="./references#CD005437-bbs2-0022" title="Perea‐MillaE , OlallaJ , Sanchez‐CantalejoE , MartosF , Matute‐CruzP , Carmona‐LopezG , et al. Pre‐hospital antibiotic treatment and mortality caused by invasive meningococcal disease, adjusting for indication bias. BMC Public Health2009;9:95. [Research Support, Non‐U.S. Gov't 19344518] ">Perea‐Milla 2009</a>). This is listed in the <a href="./references#CD005437-sec-0115" title="">Characteristics of excluded studies</a> table. </p> <p>Our 2013 review update retrieved 125 records (<a href="./references#CD005437-bbs2-0092" title="SudarsanamT , RupaliP , TharyanP , AbrahamOC , ThomasK . Pre‐admission antibiotics for suspected cases of meningococcal disease. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD005437.pub3] ">Sudarsanam 2013</a>). We identified no relevant trials. </p> <p>This 2017 update retrieved 77 records. We identified no relevant trials (<a href="#CD005437-fig-0001">Figure 1</a>). </p> </section> <section id="CD005437-sec-0059"> <h4 class="title">Included studies</h4> <p>Our protocol predefined participants as those with suspected cases of meningococcal meningitis awaiting transfer to hospital and randomised to treatment before confirmation of diagnosis. The trial by <a href="./references#CD005437-bbs2-0001" title="NathanN , BorelT , DjiboA , EvansD , DjiboS , CortyJF , et al. Ceftriaxone as effective as long‐acting chloramphenicol in short‐course treatment of meningococcal meningitis during epidemics: a randomised non‐inferiority study. Lancet2005;366:308‐13. ">Nathan 2005</a>, funded by Médecins Sans Frontières, was conducted between March and April 2003 in Niger, during an epidemic of meningococcal infection, and recruited people with suspected meningococcal meningitis from one of eight peripheral health centres, as well from a regional hospital at Zinder, Niger. </p> <p>Clarifications from the trial authors revealed that anyone presenting with suspected meningitis to any site included in the study, who met the inclusion criteria, was invited to participate. If informed consent was obtained, a lumbar puncture was conducted (along with a rapid diagnostic test for malaria), and the participant was then randomised to the interventions. Participants remained at the site to which they had initially presented (and had received the intervention) for a minimum of 72 hours of follow‐up. If a second treatment dose was required, or if an alternative treatment was necessary, these too were administered at the original site. No transfer of participants between sites occurred. Of the 510 participants originally included in the study, 97 (19%) were recruited at the National Hospital in Zinder and 41 (8%) at a district hospital in Matameye. The trial authors clarified that the hospital in Matameye was a hospital by name, but had no medical facilities beyond those of the other health centres. The remaining 372 (73%) were treated in peripheral health centres. </p> <p>We felt that as 81% of participants were treated in what were effectively peripheral health centres, and since participants were randomised to the interventions before confirmation of diagnosis, the data from this trial could be used without biasing our review's stated objectives. </p> <p>The sample size in this trial was chosen to show non‐inferiority between the two groups (less than 10% difference in the failure rate between the two groups at 72 hours) for the primary outcome of treatment failure (death at 72 hours or clinical failure). Most participants (˜55% to 57%) were in the five‐to‐14‐years age group, with 31% under the age of five years but greater than two months old. The trial evaluated the effects of a single intramuscular dose of ceftriaxone (a third‐generation cephalosporin) and a single dose of oily chloramphenicol (long‐acting intramuscular chloramphenicol) in people suspected of having meningococcal disease. This trial is further described in the <a href="./references#CD005437-sec-0114" title="">Characteristics of included studies</a> table. </p> </section> <section id="CD005437-sec-0060"> <h4 class="title">Excluded studies</h4> <p>Thirty‐one studies are described in the <a href="./references#CD005437-sec-0115" title="">Characteristics of excluded studies</a> table. We excluded nine as they randomised only proven, not suspected, cases of meningitis (<a href="./references#CD005437-bbs2-0004" title="BarsonWJ , MillerMA , BradyMT , PowellDA . Prospective comparative trial of ceftriaxone vs. conventional therapy for treatment of bacterial meningitis in children. Pediatric Infectious Disease1985;4(4):362‐8. [CN‐00039069] ">Barson 1985</a>; <a href="./references#CD005437-bbs2-0008" title="CongeniBL . Comparison of ceftriaxone and traditional therapy of bacterial meningitis. Antimicrobial Agents &amp; Chemotherapy1984;25(1):40‐4. [CN‐00033949] ">Congeni 1984</a>; <a href="./references#CD005437-bbs2-0009" title="delRioMA , ChraneD , SheltonS , McCrackenGHJr , NelsonJD . Ceftriaxone versus ampicillin and chloramphenicol for treatment of bacterial meningitis in children. Lancet1983;321(8336):1241‐4. [CN‐00031211] ">del Rio 1983</a>; <a href="./references#CD005437-bbs2-0015" title="KavaliotisJ , ManiosSG , KansouzidouA , DanielidisV . Treatment of childhood bacterial meningitis with ceftriaxone once daily: open, prospective, randomized, comparative study of short‐course versus standard‐length therapy. Chemotherapy1989;35(4):296‐303. [CN‐00061937] ">Kavaliotis 1989</a>; <a href="./references#CD005437-bbs2-0017" title="MartinE , HohlP , GuggiT , KayserFH , FernexM . Short course single daily ceftriaxone monotherapy for acute bacterial meningitis in children: results of a Swiss multicenter study. Part I: clinical results. Infection1990;18(2):70‐7. [CN‐00067277] ">Martin 1990</a>; <a href="./references#CD005437-bbs2-0018" title="MolyneuxE , NizamiSQ , SahaS , HuuKT , AzamM , BhuttaZA , et al. 5 versus 10 days of treatment with ceftriaxone for bacterial meningitis in children: a double‐blind randomised equivalence study. Lancet2011;377(9780):1837‐45. ">Molyneux 2011</a>; <a href="./references#CD005437-bbs2-0021" title="PecoulB , VaraineF , KeitaM , SogaG , DjiboA , SoulaG , et al. Long‐acting chloramphenicol versus intravenous ampicillin for treatment of bacterial meningitis. Lancet1991;338(8771):862‐6. [CN‐00078644] ">Pecoul 1991</a>; <a href="./references#CD005437-bbs2-0025" title="RodriguezWJ , PuigJR , KhanWN , FerisJ , GoldBG , SturlaC . Ceftazidime vs. standard therapy for pediatric meningitis: therapeutic, pharmacologic and epidemiologic observations. Pediatric Infectious Disease1986;5(4):408‐15. [CN‐00043513] ">Rodriguez 1986</a>; <a href="./references#CD005437-bbs2-0028" title="SchaadUB , SuterS , Gianella‐BorradoriA , PfenningerJ , AuckenthalerR , BernathO , et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial meningitis in children. New England Journal of Medicine1990;322(3):141‐7. [CN‐00064505] ">Schaad 1990</a>). The other two were RCTs of the effects of dexamethasone in children with proven bacterial meningitis with both groups receiving antibiotics (<a href="./references#CD005437-bbs2-0011" title="GirgisNI , FaridZ , MikhailIA , FarragI , SultanY , KilpatrickME . Dexamethasone treatment for bacterial meningitis in children and adults. Pediatric Infectious Disease Journal1989;8(12):848‐51. [CN‐00066058] ">Girgis 1989</a>; <a href="./references#CD005437-bbs2-0031" title="WaldER , KaplanSL , MasonEOJ , SaboD , RossL , ArditiM , et al. Dexamethasone therapy for children with bacterial meningitis. Pediatrics1995;95(1):21‐31. [CN‐00174080] ">Wald 1995</a>). A report of mortality following pre‐admission antibiotics in suspected meningococcal meningitis was a retrospective case‐control study (<a href="./references#CD005437-bbs2-0013" title="HarndenA , NinisN , ThompsonM , PereraR , LevinM , MantD , et al. Parenteral penicillin for children with meningococcal disease before hospital admission: case‐control study. BMJ2006;332(7553):1295‐8. [DOI: 10.1136/bmj.38789.723611.55] ">Harnden 2006</a>). <a href="./references#CD005437-bbs2-0022" title="Perea‐MillaE , OlallaJ , Sanchez‐CantalejoE , MartosF , Matute‐CruzP , Carmona‐LopezG , et al. Pre‐hospital antibiotic treatment and mortality caused by invasive meningococcal disease, adjusting for indication bias. BMC Public Health2009;9:95. [Research Support, Non‐U.S. Gov't 19344518] ">Perea‐Milla 2009</a> was also a retrospective case‐control study adjusted for indication bias. <a href="./references#CD005437-bbs2-0024" title="RiordanFAI . Improving promptness of antibiotic treatment in meningococcal disease. Emergency Medicine Journal2001;18(3):162‐3. [MEDLINE: 2002028693] ">Riordan 2001</a> was a prospective cohort where the intervention being studied was the effect of training on 'door to needle time' for giving antibiotics. Most other studies were observational case‐control, case series, or review articles. </p> </section> </section> <section id="CD005437-sec-0061"> <h3 class="title">Risk of bias in included studies</h3> <p>We found no RCTs or quasi‐RCTs comparing pre‐admission antibiotics for suspected meningococcal infection versus placebo or no intervention. The trial by <a href="./references#CD005437-bbs2-0001" title="NathanN , BorelT , DjiboA , EvansD , DjiboS , CortyJF , et al. Ceftriaxone as effective as long‐acting chloramphenicol in short‐course treatment of meningococcal meningitis during epidemics: a randomised non‐inferiority study. Lancet2005;366:308‐13. ">Nathan 2005</a>, comparing two antibiotics, had the following characteristics. </p> <section id="CD005437-sec-0062"> <h4 class="title">Allocation</h4> <p>This trial used off‐site computer‐generated codes in blocks of 20. Sealed, numbered, opaque envelopes containing the description of the allocated intervention were delivered to each intervention site in lots of 50 to be opened sequentially by on‐site study physicians who, after obtaining consent and a sample of CSF for diagnostic confirmation, administered the intervention. The study investigators involved in random sequence generation were not involved in recruitment of the study participants. </p> </section> <section id="CD005437-sec-0063"> <h4 class="title">Blinding</h4> <p>The study physicians were not blinded to the interventions once participants were allocated. However, the pre‐stated outcomes were objective and unlikely to be influenced by assessor bias. </p> </section> <section id="CD005437-sec-0064"> <h4 class="title">Incomplete outcome data</h4> <p>A total of 510 participants were randomised, 251 to receive ceftriaxone and 259 to receive chloramphenicol. Three participants left the treatment facility in the ceftriaxone arm and four in the chloramphenicol arm within the 72 hours of follow‐up. Reasons were not provided, but it would be difficult to assume that they had poor outcomes. Data on these participants were not included in the ITT analysis reported by the trial authors, but the numbers were few and similar in both arms, so we used data provided in the ITT analysis in the report for evaluating outcomes. We also used as presented data provided in the report on those participants in whom bacteriologic confirmation of meningococcal meningitis was done. </p> </section> <section id="CD005437-sec-0065"> <h4 class="title">Selective reporting</h4> <p>The trial protocol was not available, and the report did not have any identification to suggest that it had been prospectively registered in a publicly accessible database. However, the trial reported all pre‐stated and expected outcomes and appeared to be free of selective reporting. </p> </section> <section id="CD005437-sec-0066"> <h4 class="title">Other potential sources of bias</h4> <p>We identified no other potential sources of bias.</p> </section> </section> <section id="CD005437-sec-0067"> <h3 class="title" id="CD005437-sec-0067">Effects of interventions</h3> <p>See: <a href="./full#CD005437-tbl-0001"><b>Summary of findings for the main comparison</b> Ceftriaxone versus long‐acting (oily) chloramphenicol in people suspected to have meningococcal disease</a> </p> <p>We found no trials that evaluated the effects of pre‐admission antibiotics versus placebo for suspected cases of meningococcal disease. </p> <p>The one included trial screened 557 participants and randomised 510, of whom 251 were given intramuscular ceftriaxone and 259 long‐acting intramuscular (oily) chloramphenicol during an epidemic of meningococcal meningitis (<a href="./references#CD005437-bbs2-0001" title="NathanN , BorelT , DjiboA , EvansD , DjiboS , CortyJF , et al. Ceftriaxone as effective as long‐acting chloramphenicol in short‐course treatment of meningococcal meningitis during epidemics: a randomised non‐inferiority study. Lancet2005;366:308‐13. ">Nathan 2005</a>). </p> <section id="CD005437-sec-0068"> <h4 class="title">Primary outcomes</h4> <section id="CD005437-sec-0069"> <h5 class="title">1. Mortality</h5> <p>Data were only available for short‐term outcomes, as defined in the <a href="#CD005437-sec-0037">Types of outcome measures</a> section. At 72 hours, deaths occurred in 14 out of 247 (6%) participants in the ceftriaxone arm and 12 out of 256 (5%) participants in the long‐acting chloramphenicol arm (ITT values from the report). Mortality did not differ significantly between the two interventions (RR 1.21, 95% CI 0.57 to 2.56; N = 503; moderate‐quality evidence) (<a href="#CD005437-fig-0003">Figure 3</a>; <a href="./references#CD005437-fig-0006" title="">Analysis 1.1</a>). A subgroup analysis of the participants who were later confirmed to have meningococcal disease also failed to show any difference in mortality between the two study arms (RR 1.11, 95% CI 0.35 to 3.56; N = 308). Mortality did not differ in the remaining 195 participants in the intervention arms without confirmed meningococcal meningitis (RR 1.42, 95% CI 0.54 to 3.76). We did not undertake formal tests for subgroup differences since the confidence intervals for subgroup effects overlapped considerably. </p> <div class="figure" id="CD005437-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Ceftriaxone versus long‐acting (oily) chloramphenicol, outcome: 1.1 Death" data-id="CD005437-fig-0003" src="/cdsr/doi/10.1002/14651858.CD005437.pub4/media/CDSR/CD005437/image_n/nCD005437-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Ceftriaxone versus long‐acting (oily) chloramphenicol, outcome: 1.1 Death </p> </div> </div> </div> <p>There were no data on mortality before presentation to the health centres or after discharge from the facilities, though all participants were discharged only when well. </p> </section> <section id="CD005437-sec-0070"> <h5 class="title">2. Lack of clinical improvement</h5> <p>This composite outcome was defined as a Glasgow Coma Scale of less than 11 at 24 hours or less than 13 at 48 hours; no improvement or worsening in the state of consciousness or neurological status; persistent convulsions; and axillary temperature above 38.5° C. The ITT analysis reported that clinical failure occurred in 8 out of 233 (3%) participants in the ceftriaxone arm and 8 out of 244 (4%) participants in the long‐acting chloramphenicol arm. Again, this difference was not statistically significant (RR 0.83, 95% CI 0.32 to 2.15; N = 477; moderate‐quality evidence) (<a href="#CD005437-fig-0004">Figure 4</a>; <a href="./references#CD005437-fig-0007" title="">Analysis 1.2</a>). The interventions did not differ in the proportions of those with clinical failure in the 308 confirmed cases of meningococcal meningitis (RR 1.39, 95% CI 0.23 to 8.47), nor in the 169 participants in whom meningococcal meningitis was not confirmed (RR 0.81, 95% CI 0.25 to 2.58). The interventions did not differ significantly in the proportions of participants requiring a second injection between 48 to 72 hours (risk difference ‐0.9%, 95% CI ‐4.7% to 3.0%). </p> <div class="figure" id="CD005437-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Ceftriaxone versus long‐acting (oily) chloramphenicol, outcome: 1.2 Clinical failure" data-id="CD005437-fig-0004" src="/cdsr/doi/10.1002/14651858.CD005437.pub4/media/CDSR/CD005437/image_n/nCD005437-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Ceftriaxone versus long‐acting (oily) chloramphenicol, outcome: 1.2 Clinical failure </p> </div> </div> </div> </section> <section id="CD005437-sec-0071"> <h5 class="title">3. Morbidity</h5> <p>Neurological sequelae were recorded in 16 out of 233 (7%) participants in the ceftriaxone arm and 13 out of 244 (5%) participants in the chloramphenicol arm. Sequelae included hearing impairment in 14 participants and motor dysfunction in 15 participants (ataxia, motor deficit, or both), but data for individual sequelae were not separable by intervention arms. </p> <p>The incidence of sequelae did not differ significantly between interventions among all participants using the ITT analysis in the report (RR 1.29, 95% CI 0.63 to 2.62; N = 477; low‐quality evidence) (<a href="#CD005437-fig-0005">Figure 5</a>; <a href="./references#CD005437-fig-0008" title="">Analysis 1.3</a>). The incidence in those with confirmed meningococcal meningitis was also not significantly different (RR 1.44, 95% CI 0.65 to 3.23; N = 297), nor did it differ significantly in those without confirmed meningococcal meningitis (RR 0.64, 95% CI 0.12 to 3.40; N = 180). </p> <div class="figure" id="CD005437-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Ceftriaxone versus long‐acting (oily) chloramphenicol, outcome: 1.3 Neurological sequelae" data-id="CD005437-fig-0005" src="/cdsr/doi/10.1002/14651858.CD005437.pub4/media/CDSR/CD005437/image_n/nCD005437-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Ceftriaxone versus long‐acting (oily) chloramphenicol, outcome: 1.3 Neurological sequelae </p> </div> </div> </div> </section> </section> <section id="CD005437-sec-0072"> <h4 class="title">Secondary outcomes</h4> <section id="CD005437-sec-0073"> <h5 class="title">1. Burden of disease</h5> <p>No data were available on the burden of disease on the family, individual, or caregiver as participants were followed up only until discharge. </p> </section> <section id="CD005437-sec-0074"> <h5 class="title">2. Adverse effects</h5> <p>Neither intervention was associated with adverse effects.</p> </section> <section id="CD005437-sec-0075"> <h5 class="title">3. Economic costs of the intervention</h5> <p>The trial reported that the average treatment dose used was 2 g per person for both drugs. The treatment cost per patient was estimated as USD 4 to 6 for chloramphenicol and USD 2 to 3 for ceftriaxone. No details were provided on how these costs were arrived at or of other economic issues such as resource use, etc. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD005437-sec-0076" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD005437-sec-0076"></div> <section id="CD005437-sec-0077"> <h3 class="title" id="CD005437-sec-0077">Summary of main results</h3> <section id="CD005437-sec-0078"> <h4 class="title">Pre‐admission antibiotics versus no antibiotics</h4> <p>Our primary question regarding the efficacy and safety of pre‐admission antibiotics in decreasing mortality or morbidity in people with suspected meningococcal disease remains unanswered, since we did not find any RCTs comparing antibiotics versus placebo or no antibiotic in suspected cases of meningococcal meningitis and the initiation of antibiotics in the control group after confirmation of the diagnosis. </p> </section> <section id="CD005437-sec-0079"> <h4 class="title">Comparison of a third‐generation cephalosporin (ceftriaxone) versus long‐acting chloramphenicol</h4> <p>The sole eligible RCT included in this review reported that a single dose of ceftriaxone was not inferior to long‐acting chloramphenicol in preventing mortality, neurological sequelae, the need for a second injection, and clinical non‐response (in the first 48 hours after admission), in those with suspected, and those subsequently confirmed, to have meningococcal meningitis who were given the antibiotic at presentation to the healthcare facility during an epidemic of meningitis (<a href="./full#CD005437-tbl-0001">summary of findings Table for the main comparison</a>) (<a href="./references#CD005437-bbs2-0001" title="NathanN , BorelT , DjiboA , EvansD , DjiboS , CortyJF , et al. Ceftriaxone as effective as long‐acting chloramphenicol in short‐course treatment of meningococcal meningitis during epidemics: a randomised non‐inferiority study. Lancet2005;366:308‐13. ">Nathan 2005</a>). No adverse events were reported for either drug, and costs were comparable. </p> <p>The trial excluded very ill participants (people in an unresponsive coma and in shock), thus leaving unanswered the question of the efficacy of the schedule of treatments in such instances and the role of supportive measures, even if antibiotics were to be given early. Even among those with a less severe illness at the start of the trial, treatment failure at 72 hours and death were significantly more likely in those with impaired consciousness prior to admission (univariate odds ratio 5.51, 95% CI 2.90 to 10.45). This suggests that a single dose of antibiotics prior to admission may be insufficient to prevent negative outcomes in some people with moderately severe illness, perhaps due to suboptimal dosage, the toxic effects of rapid bacteriolysis, or the absence of adequate additional interventions to combat or prevent haemodynamic imbalance, respiratory distress, renal insufficiency, dehydration or overhydration, and electrolyte imbalance (<a href="./references#CD005437-bbs2-0062" title="KeeleyD . Parenteral penicillin before admission to hospital for meningitis. BMJ2006;332:1283‐4. ">Keeley 2006</a>). These speculations are borne out by experiences with intensive treatment of meningococcal disease elsewhere (<a href="./references#CD005437-bbs2-0038" title="BooyR , HabibiP , NadelS , deMunterC , Britto MorrisonJA , LevinM , et al. Reduction in case fatality rate from meningococcal disease associated with improved healthcare delivery. Archives of Disease in Childhood2001;85:386‐90. ">Booy 2001</a>), though the speculation on the toxic effects of rapid bacteriolysis due to antibiotic treatment have not been borne out uniformly by empiric enquiry (<a href="./references#CD005437-bbs2-0080" title="StephensDS ,  GreenwoodB ,  BrandtzaegP . Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet2007;369:2196‐201. ">Stephens 2007</a>). </p> </section> </section> <section id="CD005437-sec-0080"> <h3 class="title" id="CD005437-sec-0080">Overall completeness and applicability of evidence</h3> <section id="CD005437-sec-0081"> <h4 class="title">Completeness</h4> <p>We found no reliable evidence on the relative efficacy of giving antibiotics before confirmation of the diagnosis or withholding them until confirmation of the diagnosis. </p> <p>We believe that we have identified all trials relevant to this review.</p> </section> <section id="CD005437-sec-0082"> <h4 class="title">Applicability</h4> <p>The trial by <a href="./references#CD005437-bbs2-0001" title="NathanN , BorelT , DjiboA , EvansD , DjiboS , CortyJF , et al. Ceftriaxone as effective as long‐acting chloramphenicol in short‐course treatment of meningococcal meningitis during epidemics: a randomised non‐inferiority study. Lancet2005;366:308‐13. ">Nathan 2005</a> provided moderate‐quality evidence to endorse the use of a single dose of either ceftriaxone or oily chloramphenicol in reducing mortality, though the short follow‐up precludes the drawing of valid conclusions regarding neurological sequelae. </p> <p>The external validity of this trial is less clear. When generalising the results to settings and periods other than during epidemics, as in this trial, it is uncertain whether similar mortality and morbidity estimates would be achieved in the absence of high levels of treatment‐seeking and alertness to the possibility of meningococcal meningitis that epidemics engender. </p> <p>The oily suspension of chloramphenicol is ideal for use in low‐income countries, due to the comparable efficacy of a single intramuscular dose, repeated if needed after 48 hours, to 10 days of intravenous ampicillin given four times a day (<a href="./references#CD005437-bbs2-0021" title="PecoulB , VaraineF , KeitaM , SogaG , DjiboA , SoulaG , et al. Long‐acting chloramphenicol versus intravenous ampicillin for treatment of bacterial meningitis. Lancet1991;338(8771):862‐6. [CN‐00078644] ">Pecoul 1991</a>), achieved at a 10th of the cost. Widespread resistance to chloramphenicol in high‐income countries limits its usefulness in these settings. However, long‐acting chloramphenicol may be a useful drug of choice in low‐income countries where resistance to chloramphenicol is not a major problem and if supply is not compromised (<a href="./references#CD005437-bbs2-0066" title="PecoulB , ChiracP , TrouillerP , PinelJ , PecoulB , ChiracP , et al. Access to essential drugs in poor countries: a lost battle?. JAMA1999;281(4):361‐7. ">Pecoul 1999</a>). </p> <p>Ceftriaxone was initially around six to 10 times more expensive than long‐acting chloramphenicol, but patent rights for ceftriaxone have expired in most countries, and the generic drug costs have also fallen (<a href="./references#CD005437-bbs2-0001" title="NathanN , BorelT , DjiboA , EvansD , DjiboS , CortyJF , et al. Ceftriaxone as effective as long‐acting chloramphenicol in short‐course treatment of meningococcal meningitis during epidemics: a randomised non‐inferiority study. Lancet2005;366:308‐13. ">Nathan 2005</a>). Given the comparative efficacy and costs of both agents evaluated in the included trial, the choice of drug for initial pre‐admission antibiotic therapy would depend on the proportion of people with chloramphenicol resistance among the population in question, and the affordability of ceftriaxone at local costs. When antibiotic susceptibility testing is limited in low‐income countries with emerging chloramphenicol resistance, oily chloramphenicol as the initial drug followed by ceftriaxone, if symptoms do not improve within 48 hours and bacterial meningitis is confirmed, is a possible strategy (<a href="./references#CD005437-bbs2-0045" title="DukeT , MichaelA , MokelaD , WalT , ReederJ . Chloramphenicol or ceftriaxone, or both, as treatment for meningitis in developing countries?. Archives of Disease in Childhood2003;88(6):536‐9. ">Duke 2003</a>). Ceftriaxone could be used as the first‐line drug in the presence of widespread chloramphenicol resistance, though the emergence of resistance to ceftriaxone could also result if this use was indiscriminate. Ceftriaxone would also be preferable to chloramphenicol in situations where the suspected case of meningococcal meningitis is caused by <i>H influenzae</i> or <i>S pneumoniae</i>, where chloramphenicol is not as effective. </p> <p>The other factor that would influence the choice of antibiotic is safety. Both drugs were considered safe in the trial by <a href="./references#CD005437-bbs2-0001" title="NathanN , BorelT , DjiboA , EvansD , DjiboS , CortyJF , et al. Ceftriaxone as effective as long‐acting chloramphenicol in short‐course treatment of meningococcal meningitis during epidemics: a randomised non‐inferiority study. Lancet2005;366:308‐13. ">Nathan 2005</a>. </p> <p>Additional caveats must be considered before instituting pre‐admission antibiotics in areas with and without epidemic meningitis. One is the need to rule out other common infections with similar presentations, such as malaria, and meningitis due to other infective pathogens. The alarm engendered by epidemics or local outbreaks may also result in the indiscriminate use of antibiotics. In the included trial malaria was diagnosed in 44 (9%) of participants, and three cases of meningitis were due to <i>H influenzae</i> and three to <i>S pneumoniae</i>; moreover 133 (23%) had sterile lumbar punctures (<a href="./references#CD005437-bbs2-0001" title="NathanN , BorelT , DjiboA , EvansD , DjiboS , CortyJF , et al. Ceftriaxone as effective as long‐acting chloramphenicol in short‐course treatment of meningococcal meningitis during epidemics: a randomised non‐inferiority study. Lancet2005;366:308‐13. ">Nathan 2005</a>)<i>.</i> </p> <p>The other caveat is that unless early initiation of antibiotics in suspected cases of meningococcal disease is accompanied by other measures to improve healthcare delivery (increased recognition and case detection, early transfer to hospital and facilities, and the rapid initiation of supportive measures to manage complications of the more severe forms of the illness), the benefits of antibiotics alone are unlikely to affect mortality rates significantly (<a href="./references#CD005437-bbs2-0038" title="BooyR , HabibiP , NadelS , deMunterC , Britto MorrisonJA , LevinM , et al. Reduction in case fatality rate from meningococcal disease associated with improved healthcare delivery. Archives of Disease in Childhood2001;85:386‐90. ">Booy 2001</a>; <a href="./references#CD005437-bbs2-0065" title="National Collaborating Centre for Women’s and Children’s Health. Bacterial meningitis and meningococcal septicaemia: the management of bacterial meningitis and meningococcal septicaemia in children and young people younger than 16 years in primary and secondary care. NICE Clinical Guideline CG 102. www.nice.org.uk/CG102 (accessed prior to 2 June 2017). ">NICE 2010</a>). </p> </section> </section> <section id="CD005437-sec-0083"> <h3 class="title" id="CD005437-sec-0083">Quality of the evidence</h3> <section id="CD005437-sec-0084"> <h4 class="title">Design and quality of reporting</h4> <p>The included trial was designed to demonstrate non‐inferiority of ceftriaxone to chloramphenicol, assuming 15% of those allocated to chloramphenicol would be treatment failures, a difference of less than 10% between the interventions, a one‐sided 5% significance level, 80% power, and 10% loss to follow‐up. The trial authors stated that they calculated the risk difference and 90% CIs of the primary and secondary outcomes and considered the difference as equivalent if the upper limit of its 90% CI was below 10%. </p> <p>Non‐inferiority trials present particular difficulties in design, conduct, analysis, and interpretation, as do trials assessing equivalence. True equivalence is difficult to prove, but the assumption of equivalence in this instance was based on the demonstration of non‐inferiority initially, using one‐sided 5% significance and a one‐sided 90% CI. Equivalence was then assessed using a pre‐stated one‐sided 90% CI of less than 10% (a two‐sided CI might have been more appropriate) and an ITT analysis. The design, conduct, reporting, and interpretation of this trial conformed to the recommendations in the extension to the CONSORT statement for non‐inferiority and equivalence trials (<a href="./references#CD005437-bbs2-0068" title="PiaggioG , ElbourneD , AltmanDG , PocockSJ , EvansSJW , for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. An extension of the CONSORT statement. JAMA2006;295:1152‐60. ">Piaggio 2006</a>). We considered the study to be adequate in reporting randomisation, allocation concealment, and attrition, and although it was an open‐label trial, we considered the risk of detection bias to be low due to the objective outcomes used. </p> </section> <section id="CD005437-sec-0085"> <h4 class="title">Overall quality of the evidence</h4> <p>We rated the overall quality of the evidence for primary outcomes as moderate, and although there were no limitations in study design, we downgraded the trial for indirectness for all outcomes due to the exclusion of infants, pregnant women, and those with severe disease (<a href="./full#CD005437-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>We further downgraded the quality of the evidence to low for neurological outcomes since the duration of follow‐up was only 72 hours and was deemed too short to adequately detect neurological outcomes. Trials that assess deficits in the longer term would enable the detection of neurological sequelae that are detected only after discharge, particularly hearing deficits and spasticity in young children, and milder cognitive deficits and behavioural changes in adolescents (<a href="./references#CD005437-bbs2-0039" title="BorgJ , ChristieD , CoenPG , BooyR , VinerRM . Outcomes of meningococcal disease in adolescence: prospective, matched‐cohort study. Pediatrics2009;123:e502–9. [DOI: 10.1542/peds.2008‐0581] ">Borg 2009</a>). The methods used to detect these outcomes in <a href="./references#CD005437-bbs2-0001" title="NathanN , BorelT , DjiboA , EvansD , DjiboS , CortyJF , et al. Ceftriaxone as effective as long‐acting chloramphenicol in short‐course treatment of meningococcal meningitis during epidemics: a randomised non‐inferiority study. Lancet2005;366:308‐13. ">Nathan 2005</a> were based on gross clinical evaluation and may also have been insensitive to detect them accurately. </p> <p>The trial may also have been underpowered to demonstrate non‐inferiority for neurological outcomes in confirmed cases of meningococcal meningitis, and the follow‐up was too short, therefore we judged the quality of the evidence for this subgroup as very low (<a href="./full#CD005437-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> </section> <section id="CD005437-sec-0086"> <h3 class="title" id="CD005437-sec-0086">Potential biases in the review process</h3> <p>Despite the importance of the issue, the surprising lack of RCTs for our main objective is worrying. While it may suggest that we were unable to locate small trials, particularly those with inconclusive results, and indicate publication or retrieval bias, our search of multiple sources with no language restrictions reassures us that this is unlikely. A more credible explanation is that pre‐admission antibiotics have become the standard of care in many countries and hence an RCT, especially a placebo‐controlled trial, may be deemed unethical. </p> <p>At first reading, the sole included trial seemed to not fulfil our inclusion criteria of 'pre‐admission' use of antibiotics (<a href="./references#CD005437-bbs2-0001" title="NathanN , BorelT , DjiboA , EvansD , DjiboS , CortyJF , et al. Ceftriaxone as effective as long‐acting chloramphenicol in short‐course treatment of meningococcal meningitis during epidemics: a randomised non‐inferiority study. Lancet2005;366:308‐13. ">Nathan 2005</a>), since participants were those treated in health centres; written communication with trial authors confirmed that the first dose of antibiotic was administered to people suspected as having meningococcal meningitis prior to seeking confirmation of the diagnosis. The trial authors also clarified that the majority of the treatment facilities (8/9) were primary care centres, and the majority of participants were treated at these centres (81%). The results of this trial also showed that 195/503 (39%) randomised participants were not subsequently confirmed to have meningococcal meningitis on culture or by polymerase chain reaction, attesting to the actual use of antibiotics prior to disease confirmation and the suitability of this trial for inclusion in this review. None of the excluded RCTs fulfilled this definition of antibiotic use. </p> </section> <section id="CD005437-sec-0087"> <h3 class="title" id="CD005437-sec-0087">Agreements and disagreements with other studies or reviews</h3> <section id="CD005437-sec-0088"> <h4 class="title">Pre‐admission antibiotics versus no antibiotics</h4> <p>The available evidence for this comparison comes from retrospective case series, case‐control, and cohort studies. Considering the non‐specific nature of symptoms, especially in milder cases and in young children, and the lack of sensitivity of the specific clinical signs of both Kernig and Brudzinski, in adults as well as in children (<a href="./references#CD005437-bbs2-0048" title="ElBashirH , LaundyM , BooyR . Diagnosis and treatment of bacterial meningitis. Archives of Disease in Childhood2003;88:615‐20. ">El Bashir 2003</a>), it is likely that data from these sources are confounded by diagnostic errors and inclusion of the more severely ill (<a href="./references#CD005437-bbs2-0055" title="HahnéSJM , CharlettA , PurcellB , SamuelssonS , CamaroniI , EhrhardI , et al. Effectiveness of antibiotics given before admission in reducing mortality from meningococcal disease: systematic review. BMJ2006;332:1299‐303. ">Hahné 2006</a>; <a href="./references#CD005437-bbs2-0013" title="HarndenA , NinisN , ThompsonM , PereraR , LevinM , MantD , et al. Parenteral penicillin for children with meningococcal disease before hospital admission: case‐control study. BMJ2006;332(7553):1295‐8. [DOI: 10.1136/bmj.38789.723611.55] ">Harnden 2006</a>; <a href="./references#CD005437-bbs2-0062" title="KeeleyD . Parenteral penicillin before admission to hospital for meningitis. BMJ2006;332:1283‐4. ">Keeley 2006</a>; <a href="./references#CD005437-bbs2-0029" title="SorensenHT , NielsenGL , SchonheyderHC , SteffensenFH , HansenI , SabroeS , et al. Outcome of pre‐hospital antibiotic treatment of meningococcal disease. Journal of Clinical Epidemiology1998;51(9):717‐21. [MEDLINE: 1998321631] ">Sorensen 1998</a>). The latter are more likely to seek help in clinic‐based studies, be perceived to have meningitis by clinicians in these and in community‐based studies, and to be treated with parenteral antibiotics early, leading to 'indication bias' (<a href="./references#CD005437-bbs2-0022" title="Perea‐MillaE , OlallaJ , Sanchez‐CantalejoE , MartosF , Matute‐CruzP , Carmona‐LopezG , et al. Pre‐hospital antibiotic treatment and mortality caused by invasive meningococcal disease, adjusting for indication bias. BMC Public Health2009;9:95. [Research Support, Non‐U.S. Gov't 19344518] ">Perea‐Milla 2009</a>). Consequently, the often paradoxical outcomes of these observational studies, both positive and negative, are confounded by disease severity, and the proportions that received pre‐admission antibiotics (<a href="./references#CD005437-bbs2-0055" title="HahnéSJM , CharlettA , PurcellB , SamuelssonS , CamaroniI , EhrhardI , et al. Effectiveness of antibiotics given before admission in reducing mortality from meningococcal disease: systematic review. BMJ2006;332:1299‐303. ">Hahné 2006</a>; <a href="./references#CD005437-bbs2-0013" title="HarndenA , NinisN , ThompsonM , PereraR , LevinM , MantD , et al. Parenteral penicillin for children with meningococcal disease before hospital admission: case‐control study. BMJ2006;332(7553):1295‐8. [DOI: 10.1136/bmj.38789.723611.55] ">Harnden 2006</a>; <a href="./references#CD005437-bbs2-0067" title="PereraR . Statistics and death from meningococcal disease in children. BMJ2006;332(7553):1297‐8. ">Perera 2006</a>). Similarly, observational studies of oral pre‐admission antibiotics that report lower mortality and morbidity are also confounded by indication bias, in this case the inclusion of people with less severe or non‐meningococcal disease (<a href="./references#CD005437-bbs2-0013" title="HarndenA , NinisN , ThompsonM , PereraR , LevinM , MantD , et al. Parenteral penicillin for children with meningococcal disease before hospital admission: case‐control study. BMJ2006;332(7553):1295‐8. [DOI: 10.1136/bmj.38789.723611.55] ">Harnden 2006</a>; <a href="./references#CD005437-bbs2-0062" title="KeeleyD . Parenteral penicillin before admission to hospital for meningitis. BMJ2006;332:1283‐4. ">Keeley 2006</a>; <a href="./references#CD005437-bbs2-0022" title="Perea‐MillaE , OlallaJ , Sanchez‐CantalejoE , MartosF , Matute‐CruzP , Carmona‐LopezG , et al. Pre‐hospital antibiotic treatment and mortality caused by invasive meningococcal disease, adjusting for indication bias. BMC Public Health2009;9:95. [Research Support, Non‐U.S. Gov't 19344518] ">Perea‐Milla 2009</a>). </p> <p>A retrospective analysis of 848 people admitted with invasive meningococcal disease, 49 of whom died (6%), from 1995 to 2000 in 31 hospitals in Spain, used the 'propensity score' to assign patients the probability of receiving pre‐hospital antibiotics prior to admission, based on clinical symptoms, and matched the 228 who had received oral antibiotics in the 48 hours prior to admission with controls who had not received pre‐hospital antibiotics, again based on their propensity scores for not being thus treated (<a href="./references#CD005437-bbs2-0022" title="Perea‐MillaE , OlallaJ , Sanchez‐CantalejoE , MartosF , Matute‐CruzP , Carmona‐LopezG , et al. Pre‐hospital antibiotic treatment and mortality caused by invasive meningococcal disease, adjusting for indication bias. BMC Public Health2009;9:95. [Research Support, Non‐U.S. Gov't 19344518] ">Perea‐Milla 2009</a>). Adjusted multivariate analyses indicated that pre‐hospital antibiotics appeared to protect against death (odds ratio 0.37, 95% CI 0.15 to 0.93). The propensity score technique has been equated with randomisation in situations where randomisation is difficult, and this trial attempted to adjust for the indication bias that has confounded interpretation of previous observational studies. The imprecision of the effect estimate (the confidence intervals suggest a protective effect that could be clinically very important to only marginally important) is in concordance with evidence from case‐control studies that indicate, on balance, that early diagnosis, early admission to hospital (within three hours), and early initiation of supportive measures are as important as the early commencement of antibiotics (<a href="./references#CD005437-bbs2-0062" title="KeeleyD . Parenteral penicillin before admission to hospital for meningitis. BMJ2006;332:1283‐4. ">Keeley 2006</a>). </p> </section> <section id="CD005437-sec-0089"> <h4 class="title">Pre‐admission cephalosporins versus chloramphenicol</h4> <p>Previous NICE guidance recommended that children with suspected meningococcal disease be given parenteral antibiotics (benzylpenicillin or a third‐generation cephalosporin) at the earliest opportunity (<a href="./references#CD005437-bbs2-0064" title="National Collaborating Centre for Women's and Children's Health. Feverish illness in children. Assessment and initial management in children younger than 5 years. NICE Clinical Guideline CG47. www.nice.org.uk/nicemedia/pdf/cg47niceguideline.pdf (accessed prior to 2 June 2017). ">NICE 2007</a>). The SIGN guideline on the management of invasive meningococcal disease in children and young people recommends that parenteral antibiotics (benzylpenicillin or cefotaxime) should be given as soon as invasive meningococcal disease is suspected and even before confirmation of the diagnosis is sought (<a href="./references#CD005437-bbs2-0078" title="Scottish Intercollegiate Guidelines Network. Management of invasive meningococcal disease in children and young people. A National Clinical Guideline: 102. www.sign.ac.uk/pdf/sign102.pdf (accessed prior to 2 June 2017). ">SIGN 2008</a>). The latest NICE guidance considers transfer to hospital and fluid management of greater priority than administering pre‐hospital antibiotics, unless immediate transfer is not possible, or if the clinical suspicion of meningococcal meningitis is accompanied by a non‐blanching rash or meningococcal septicaemia (<a href="./references#CD005437-bbs2-0065" title="National Collaborating Centre for Women’s and Children’s Health. Bacterial meningitis and meningococcal septicaemia: the management of bacterial meningitis and meningococcal septicaemia in children and young people younger than 16 years in primary and secondary care. NICE Clinical Guideline CG 102. www.nice.org.uk/CG102 (accessed prior to 2 June 2017). ">NICE 2010</a>). In contrast to earlier guidance, <a href="./references#CD005437-bbs2-0065" title="National Collaborating Centre for Women’s and Children’s Health. Bacterial meningitis and meningococcal septicaemia: the management of bacterial meningitis and meningococcal septicaemia in children and young people younger than 16 years in primary and secondary care. NICE Clinical Guideline CG 102. www.nice.org.uk/CG102 (accessed prior to 2 June 2017). ">NICE 2010</a> recommends using ceftriaxone as first‐line treatment for bacterial meningitis and meningococcal disease in children and young people older than three months of age. </p> <p>An economic analysis, done from the perspective of the National Health Service (NHS) and a socialised medicine approach, strongly suggests that ceftriaxone is the most cost‐effective antibiotic for the treatment of suspected meningococcal disease or suspected meningitis in a majority of children (<a href="./references#CD005437-bbs2-0065" title="National Collaborating Centre for Women’s and Children’s Health. Bacterial meningitis and meningococcal septicaemia: the management of bacterial meningitis and meningococcal septicaemia in children and young people younger than 16 years in primary and secondary care. NICE Clinical Guideline CG 102. www.nice.org.uk/CG102 (accessed prior to 2 June 2017). ">NICE 2010</a>). This concurs with the cruder estimates in <a href="./references#CD005437-bbs2-0001" title="NathanN , BorelT , DjiboA , EvansD , DjiboS , CortyJF , et al. Ceftriaxone as effective as long‐acting chloramphenicol in short‐course treatment of meningococcal meningitis during epidemics: a randomised non‐inferiority study. Lancet2005;366:308‐13. ">Nathan 2005</a>. The NICE analyses did not take into account variations in drug prices or any effects on health or costs arising from antibiotic resistance, both of which may vary widely in different settings. These estimates also assumed that survival is the only health‐related quality of life outcome of importance with antibiotic use and did not consider other outcomes such as prevention of neurological disability and its (more difficult to estimate) consequences and associated costs, and quality adjusted life years (QALYs) lost or gained. </p> </section> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD005437-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005437.pub4/media/CDSR/CD005437/urn:x-wiley:14651858:media:CD005437:CD005437-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005437.pub4/media/CDSR/CD005437/image_t/tCD005437-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD005437-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005437.pub4/media/CDSR/CD005437/image_n/nCD005437-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005437.pub4/full#CD005437-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005437.pub4/media/CDSR/CD005437/image_n/nCD005437-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005437-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005437.pub4/media/CDSR/CD005437/urn:x-wiley:14651858:media:CD005437:CD005437-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005437.pub4/media/CDSR/CD005437/image_t/tCD005437-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for Nathan 2005." data-id="CD005437-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005437.pub4/media/CDSR/CD005437/image_n/nCD005437-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for <a href="./references#CD005437-bbs2-0001" title="NathanN , BorelT , DjiboA , EvansD , DjiboS , CortyJF , et al. Ceftriaxone as effective as long‐acting chloramphenicol in short‐course treatment of meningococcal meningitis during epidemics: a randomised non‐inferiority study. Lancet2005;366:308‐13. ">Nathan 2005</a>. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005437.pub4/full#CD005437-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005437.pub4/media/CDSR/CD005437/image_n/nCD005437-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005437-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005437.pub4/media/CDSR/CD005437/urn:x-wiley:14651858:media:CD005437:CD005437-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005437.pub4/media/CDSR/CD005437/image_t/tCD005437-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Ceftriaxone versus long‐acting (oily) chloramphenicol, outcome: 1.1 Death" data-id="CD005437-fig-0003" src="/cdsr/doi/10.1002/14651858.CD005437.pub4/media/CDSR/CD005437/image_n/nCD005437-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Ceftriaxone versus long‐acting (oily) chloramphenicol, outcome: 1.1 Death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005437.pub4/full#CD005437-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005437.pub4/media/CDSR/CD005437/image_n/nCD005437-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005437-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005437.pub4/media/CDSR/CD005437/urn:x-wiley:14651858:media:CD005437:CD005437-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005437.pub4/media/CDSR/CD005437/image_t/tCD005437-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Ceftriaxone versus long‐acting (oily) chloramphenicol, outcome: 1.2 Clinical failure" data-id="CD005437-fig-0004" src="/cdsr/doi/10.1002/14651858.CD005437.pub4/media/CDSR/CD005437/image_n/nCD005437-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Ceftriaxone versus long‐acting (oily) chloramphenicol, outcome: 1.2 Clinical failure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005437.pub4/full#CD005437-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005437.pub4/media/CDSR/CD005437/image_n/nCD005437-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005437-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005437.pub4/media/CDSR/CD005437/urn:x-wiley:14651858:media:CD005437:CD005437-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005437.pub4/media/CDSR/CD005437/image_t/tCD005437-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Ceftriaxone versus long‐acting (oily) chloramphenicol, outcome: 1.3 Neurological sequelae" data-id="CD005437-fig-0005" src="/cdsr/doi/10.1002/14651858.CD005437.pub4/media/CDSR/CD005437/image_n/nCD005437-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Ceftriaxone versus long‐acting (oily) chloramphenicol, outcome: 1.3 Neurological sequelae </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005437.pub4/full#CD005437-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005437.pub4/media/CDSR/CD005437/image_n/nCD005437-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005437-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005437.pub4/media/CDSR/CD005437/urn:x-wiley:14651858:media:CD005437:CD005437-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005437.pub4/media/CDSR/CD005437/image_t/tCD005437-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ceftriaxone versus long‐acting (oily) chloramphenicol, Outcome 1 Death." data-id="CD005437-fig-0006" src="/cdsr/doi/10.1002/14651858.CD005437.pub4/media/CDSR/CD005437/image_n/nCD005437-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Ceftriaxone versus long‐acting (oily) chloramphenicol, Outcome 1 Death.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005437.pub4/references#CD005437-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005437.pub4/media/CDSR/CD005437/image_n/nCD005437-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005437-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005437.pub4/media/CDSR/CD005437/urn:x-wiley:14651858:media:CD005437:CD005437-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005437.pub4/media/CDSR/CD005437/image_t/tCD005437-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ceftriaxone versus long‐acting (oily) chloramphenicol, Outcome 2 Clinical failure." data-id="CD005437-fig-0007" src="/cdsr/doi/10.1002/14651858.CD005437.pub4/media/CDSR/CD005437/image_n/nCD005437-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Ceftriaxone versus long‐acting (oily) chloramphenicol, Outcome 2 Clinical failure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005437.pub4/references#CD005437-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005437.pub4/media/CDSR/CD005437/image_n/nCD005437-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005437-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005437.pub4/media/CDSR/CD005437/urn:x-wiley:14651858:media:CD005437:CD005437-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005437.pub4/media/CDSR/CD005437/image_t/tCD005437-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ceftriaxone versus long‐acting (oily) chloramphenicol, Outcome 3 Neurological sequelae." data-id="CD005437-fig-0008" src="/cdsr/doi/10.1002/14651858.CD005437.pub4/media/CDSR/CD005437/image_n/nCD005437-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Ceftriaxone versus long‐acting (oily) chloramphenicol, Outcome 3 Neurological sequelae. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005437.pub4/references#CD005437-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005437.pub4/media/CDSR/CD005437/image_n/nCD005437-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD005437-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Ceftriaxone versus long‐acting (oily) chloramphenicol in people suspected to have meningococcal disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Ceftriaxone versus long‐acting (oily) chloramphenicol in people suspected to have meningococcal disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people suspected to have meningococcal disease (adults and children)<br/> <b>Settings:</b> primary care centres in a low‐income country in Africa during an epidemic<br/> <b>Intervention:</b> intramuscular ceftriaxone (100 mg/kg; max 4 g) single dose<br/> <b>Comparison:</b> long‐acting (oily) chloramphenicol (100 mg/kg; max 3 g) single dose </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Long‐acting (oily) chloramphenicol</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Intramuscular ceftriaxone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death ‐ in all participants ‐ short term</b> <br/> Follow‐up: 72 hours </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>47 per 1000</b><sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>57 per 1000</b> <br/> (27 to 120) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.21</b> <br/> (0.57 to 2.56)<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>503<br/> (1 study)<sup>8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3,4,5,6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All outcomes in this table are from 1 trial that randomised 510 participants to either intervention (<a href="./references#CD005437-bbs2-0001" title="NathanN , BorelT , DjiboA , EvansD , DjiboS , CortyJF , et al. Ceftriaxone as effective as long‐acting chloramphenicol in short‐course treatment of meningococcal meningitis during epidemics: a randomised non‐inferiority study. Lancet2005;366:308‐13. ">Nathan 2005</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death ‐ in confirmed cases of meningococcal meningitis (subgroup)</b> <br/> Follow‐up: 72 hours </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 1000</b><sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>38 per 1000</b> <br/> (12 to 121) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.11</b> <br/> (0.35 to 3.56)<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>308<br/> (1 study)<sup>8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3,4,6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical failure ‐ in all participants ‐ short term</b> <br/> Composite clinical criteria<sup>10</sup> <br/> Follow‐up: 24 to 48 hours </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>41 per 1000</b><sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 1000</b> <br/> (13 to 84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.83</b> <br/> (0.32 to 2.15)<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>477<br/> (1 study)<sup>8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3,4,6,7,9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical failure ‐ in confirmed cases of meningococcal meningitis (subgroup)</b> <br/> Composite clinical criteria<sup>10</sup> <br/> Follow‐up: 24 to 48 hours </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>14 per 1000</b><sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>19 per 1000</b> <br/> (3 to 107) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.39</b> <br/> (0.23 to 8.47)<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>308<br/> (1 study)<sup>8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3,4,6,7,9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neurological sequelae ‐ in all participants‐ short term</b> <br/> Clinical assessment<sup>11</sup> <br/> Follow‐up: 72 hours </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>53 per 1000</b><sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>68 per 1000</b> <br/> (33 to 139) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.29</b> <br/> (0.63 to 2.62)<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>477<br/> (1 study)<sup>8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,4,7,9,12,13</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neurological sequelae ‐ in confirmed cases of meningococcal meningitis (subgroup)</b> <br/> Clinical assesment<sup>11</sup> <br/> Follow‐up: 72 hours </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>63 per 1000</b><sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>91 per 1000</b> <br/> (41 to 203) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.44</b> <br/> (0.65 to 3.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>297<br/> (1 study)<sup>8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,4,5,7,9,12</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events ‐ short term</b> <br/> Follow‐up: 72 hours </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (1 study)<sup>8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No adverse events were detected with either intervention</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Basis of the assumed risk: control group risk.<br/> <sup>2</sup>Effect estimate: consistent with non‐inferiority of ceftriaxone versus chloramphenicol.<br/> <sup>3</sup>No serious study limitations: block randomised using off‐site computer‐generated codes in blocks of 20; allocation concealed in numbered, sealed, opaque envelopes; recruitment was by personnel not involved in generating random sequence; baseline variables matched in intervention arms; open‐label trial but outcome was objective; outcomes completely and adequately reported; no other biases.<br/> <sup>4</sup>No serious inconsistency: results for all participants and in subgroups were consistent.<br/> <sup>5</sup>Serious imprecision: sample size was estimated to demonstrate non‐inferiority for the primary outcome and not for neurological sequelae (secondary outcome). A sample size of 175 individuals with confirmed meningococcal meningitis per group (350 total) was needed for the primary outcome with a one‐sided 5% significance level, 80% power, and assuming 10% dropouts. Only 308 participants were confirmed to have meningococcal meningitis, thus trial may be underpowered to detect non‐inferiority for neurological outcomes. Downgraded by one.<br/> <sup>6</sup>No serious imprecision: trial was adequately powered to demonstrate non‐inferiority. Not downgraded.<br/> <sup>7</sup>Publication bias unlikely: search for trials was comprehensive. Not downgraded.<br/> <sup>8</sup>Parallel‐group, open‐label, non‐inferiority trial.<br/> <sup>9</sup>Serious indirectness: trial excluded infants, pregnant women, and those with serious illness (in non‐reactive coma or with convulsions). Downgraded by one.<br/> <sup>10</sup>Clinical failure: composite of: a) state of consciousness remaining severely altered (Glasgow Coma Scale &lt; 11 at 24 hours or &lt; 13 at 48 hours); b) no improvement in the state of consciousness since 0 hour; c) appearance of or worsened neurological symptoms since 0 hour; d) repeated or persistent convulsions; and e) axillary temperature above 38.5° C in the absence of other evident infectious pathological changes.<br/> <sup>11</sup>Neurological sequelae: judged on gross clinical abnormality.<br/> <sup>12</sup>Serious indirectness: follow‐up was too short to detect neurological sequelae adequately. Downgraded by one.<br/> <sup>13</sup>No serious imprecision: sample size of 350 required to demonstrate non‐inferiority for primary outcome, but sample size adequately powered to demonstrate non‐inferiority for this secondary outcome as well. Not downgraded. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Ceftriaxone versus long‐acting (oily) chloramphenicol in people suspected to have meningococcal disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005437.pub4/full#CD005437-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005437-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Ceftriaxone versus long‐acting (oily) chloramphenicol</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 In all participants ‐ short‐term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>503</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.57, 2.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 In confirmed cases of meningococcal meningitis ‐ short‐term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.35, 3.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 In cases due to other causes ‐ short‐term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.54, 3.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Clinical failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 In all participants ‐ short‐term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>477</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.32, 2.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 In confirmed cases of meningococcal meningitis ‐ short‐term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.23, 8.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 In cases due to other causes ‐ short‐term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>169</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.25, 2.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Neurological sequelae <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 In all participants ‐ short‐term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>477</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.63, 2.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 In confirmed cases of meningococcal meningitis ‐ short‐term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>297</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [0.65, 3.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 In cases due to other causes ‐ short‐term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.12, 3.40]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Ceftriaxone versus long‐acting (oily) chloramphenicol</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005437.pub4/references#CD005437-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD005437.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD005437-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD005437-note-0003">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD005437-note-0001">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD005437-note-0007">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005437\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005437\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005437\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005437\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005437\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005437\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005437\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005437\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005437\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005437\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005437\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005437\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005437\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005437\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005437\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005437\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005437\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005437\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jiwTpTuf&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005437.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005437.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD005437.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD005437.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005437.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725291290"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005437.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725291293"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005437.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e77a85d4b936e',t:'MTc0MDcyNTI5MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 